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bstract
How do functional foods affect human health? To answer this question it is important to understand what happens when food is digested and taken
p by the gastrointestinal (GI) tract. The gut is a selective nutrient absorption system and the most important signal transduction and information
xchange system within the body. It acts as a signal transducer, a neuroendocrine sensor, and an immunological recognition and presentation
ystem. It is also a complex information exchange system comprising a number of signaling networks involving GI cells and cells immobilized in
rgans or transported in blood. The bioactivity of functional foods in  vivo  may be due to their effects on such networks, but this raises the question
f what signaling pathways are used by non-nutrients that cannot be absorbed by the gut. The purpose of this review is to describe intestinal
utrient transportation, identify a number of widely expressed receptors and signal transduction pathways, and outline our current understanding
f the mechanisms involved in health and disease. At the end of the review, a method for developing a cell communication network is described.
his network is convenient for investigating the effects of oral administration of experimental medicines, drugs, or functional foods on cytokines
f interest. Because cytokines and chemokines are transported via  the circulatory system, a simple 2–3 mL blood sample from a volunteer is a rich
ource of information. This method may become the gold standard for evaluating the effects of functional foods or medicines in  vivo.
 2012 Production and hosting by Elsevier B.V. on behalf of Beijing Academy of Food Sciences.
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v.  Introduction
There has recently been a rapid increase in consumer interest
n the health-enhancing roles of specific foods or physiologi-
ally active food components, so-called functional foods [1].
enerally speaking all foods are functional as they have nutri-
ional value and are fundamental for survival. However, the
erm “functional food” has a different connotation of provid-
ng an additional physiological benefit beyond basic nutritional
equirements. For oriental cultures in particular, foods are
iewed not only as essential for survival but also as a means of
nsuring one’s health by ensuring a balanced intake of different∗ Corresponding author at: Tianjin Key Laboratory of Food Biotechnology,
ianjin 300134, China. Tel.: +86 22 26675780; fax: +86 22 26675780.
E-mail address: pgc@tjcu.edu.cn (G. Pang).
eer review under responsibility of Beijing Academy of Food Sciences.
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eijing Academy of Food Sciences.
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ioods assigned, for example, yin and yang attributions. Such
nowledge has been accumulated over thousands of years.
In contemporary societies, however, many individuals do not
onsume a balanced diet and this has led to an increase in the inci-
ence of serious metabolic imbalances. These in turn increase
he risk of diseases such as obesity, type 2 diabetes, hyperten-
ion, food allergies and intolerances, and gastrointestinal and
nflammatory disorders. Good nutrition is vital for health, opti-
al growth and development, and prevention of disease [2]. It
s now understood that nutrients and other substances obtained
rom a wide variety of foods promote health, maintain metabolic
omeostasis, and fulfill energy requirements. Unfortunately,
here is no optimal diet fit for everyone due to the extensive
ariation in human genetics, phenotypes, and cultures, and this
s why it is so important for food and nutrition scientists to deter-
ine the relationship between an individual’s metabolism and
heir diet to help them make better food choices.
The gut is an obvious target for functional foods as it is
he interface between diet and metabolic events. Key digestive
hysiological processes that can be regulated by dietary mod-
fications include satiety; the rate and extent of macronutrient
reakdown and absorption from the small bowel; metabolism;
he nature of the gut microflora, fermentation, mucosal function-
ng, bowel habits; and the gut immune system.
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Over the past few decades, a number of large non-nutrient
olecules have been identified. These include secondary
etabolites in plants that are used for defense, reproduction,
nd so on, but are not essential nutrients. Secondary metabo-
ites such as phytochemicals were mostly ignored until recently
hen their potential metabolic effects were first detected. For
xample, flavones were found to protect against heart disease
nd soy-based estrogens against cancer. Since then the bioac-
ivity of thousands of non-nutrient compounds in foods such as
ed wine, coffee, fish, and fruits and vegetables have been inves-
igated to determine their effects on animal biochemistry and
etabolism and to identify those with potential health benefits.
Probiotics are usually defined as microbial food supplements
hat have beneficial effects on consumers. Microbiologists first
eported that the microflora of the gastrointestinal (GI) tracts
f healthy individuals differed from that of diseased individ-
als, and the microflora found in the healthy individuals was
ermed probiotic. Most probiotics fall into the group of orga-
isms known as lactic acid-producing bacteria, and these are
ormally consumed in the form of yogurt, fermented milks, or
ther fermented foods. Many of the functional food products
hat have been developed include probiotics.
So how do functional foods exert their beneficial effects on
uman health? To answer this question we first have to under-
tand what happens when these foods are digested and taken
p by the GI tract. The gut is not only a selective nutrient
bsorption system; it is also the most important signal trans-
uction and information exchange system within the body. The
ut is involved in nutrient recognition and signal transduc-
ion, and also acts as a neuroendocrine sensor as well as an
mmunological recognition and presentation system. Together,
hese complex information exchange systems form a number
f signaling networks that include cells immobilized in organs
s well as cells transported via  the circulatory system. Func-
ional foods may exert their beneficial effects through these cell
ommunication networks and by interacting with various recep-
ors found along the GI tract. However, many non-nutrients,
uch as dietary fibers and oligosaccharides, exert their effects
ia signaling pathways other than those found in the gut.
The current review aims to describe intestinal nutrient trans-
ort, the regulation of signal transduction, and the various
eceptors involved in the processes outlined above. A detailed
xplanation of the mechanisms by which functional foods pro-
ect against a number of diseases is also provided.
. The  gut  as  a  system  for  regulating  both  nutrient
ptake and  signal  transduction
An understanding of the physiological regulation of nutrient
ptake is of profound importance for elucidating the modulating
ffects of abnormal conditions such as diabetes and obesity on
ntestinal absorption [3]..1. Sugar  uptake
Sodium glucose cotransporter 1 (SGLT1) is responsible
or all active glucose uptake in the intestine. The subsequent
p
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ovement of glucose across the basolateral membrane occurs
long a diffusion gradient [4]. Thus, SGLT1 is an essential
omponent of intestinal glucose absorption, and its regula-
ion is of paramount importance. Intestinal glucose absorption
s performed by two different components: Na+/glucose
otransporters and diffusive components formerly attributed to
aracellular flow [5]. Recent evidence has indicated that absorp-
ion is mediated by the transient insertion of glucose transporter
ype 2 (GLUT2) into the apical membrane. This GLUT2 path-
ay is present in many species ranging from insects to humans,
nd acts as a major route of intestinal sugar absorption. Sensing
echanisms include regulation by a newly identified calcium
bsorption pathway involving the neuroendocrine l-type chan-
el Cav1.3 during the digestion and activation of intestinal sweet
aste receptors by natural sugars, artificial sweeteners, paracrine
nd endocrine hormones (especially insulin and GLP-2), and
tress. Active transport of glucose across the enterocyte apical
embrane through SGLT1 is driven by the downhill gradient of
a+, which is maintained by the basolateral Na+/K+-ATPase [6].
hen the luminal glucose level is lower than the blood glucose
evel, SGLT1 has the unique ability to transport glucose against
ts concentration gradient and therefore to act as a very effec-
ive scavenger from the lumen in  vivo. In enterocytes, glucose
rosses the basolateral membrane into circulation via  the facil-
tative transporter GLUT2. Fructose is transported across the
pical membrane by GLUT5. Biochemical markers in previous
xperiments have suggested that intracellular Ca2+ (Cai2+) is
mportant for the glucose-induced insertion of apical GLUT2,
hich might be activated by Cai2+. Apical GLUT2 has also been
dentified in experimental diabetes and in insulin-resistant states
nduced by fructose and fat [7].
Intestinal sweet taste receptors are part of the lingual
1R family of sweet taste receptors that includes T1R1,
1R2, and T1R3. T1R3 is commonly involved in the for-
ation of T1R2+T1R3 and T1R1+T1R3 heterodimers [8].
he T1R2+T1R3 heterodimer works through two G-protein-
ediated signaling systems. These are linked to either
hospholipase C (PLC) 2 or protein kinase A and increase
ntracellular cAMP and Ca2+, respectively [9].
Sugar absorption is regulated by endocrine and paracrine hor-
ones. Insulin secretion in response to a sugar-rich meal can
ower blood glucose within minutes due to a ten-fold increase
n glucose uptake by the skeletal muscles and adipose tissues,
hich occurs as GLUT4 is translocated to the plasma membrane.
his process may explain the previously unknown hypoglycemic
ction of insulin on enterocytes. Glycemic excursions, a known
isk factor for cardiovascular disease in type 2 diabetic patients,
re smoothed during the course of a meal. [10]. Cheeseman et al.
lso reported paracrine regulation of sugar absorption, partic-
larly by gastric inhibitory polypeptide (GIP), Glucagon-like
eptide-1 (GLP-1), and GLP-2 [11].
.2.  Intestinal  lipid  absorption  and  sensingProducts of lipid hydrolysis are solubilized in micelles and
resented to the apical membranes of enterocytes. These apical
embranes contain several transport proteins that participate in
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he uptake of various types of lipids [12]. Niemann-Pick C1-like
 (NPC1L1) is one of the proteins involved in cholesterol uptake.
D36 and fatty acid (FA) transport protein (FATP) have been
ound to participate in FA transport, and the scavenger receptor
lass B type I (SR-BI) is involved in vitamin E (Vit E) uptake.
n the cytosol, FA-binding protein (FABP) and cellular retinol-
inding protein (CRBP) are responsible for the transport of FAs
nd retinol (R), respectively. In addition, enterocytes express the
TP-binding cassette (ABC) transporter A1 on their basolateral
embrane to facilitate the efflux of cholesterol. The absorption
f lipids from the intestinal lumen into the enterocytes and their
ubsequent secretion into circulation are complex processes.
ecent findings concerning the basolateral efflux of cholesterol
s high-density apoA-I-containing lipoproteins should help to
dentify additional targets for the development of drugs to sup-
ress cholesterol absorption and so reduce hypercholesterolemia
nd the risk of cardiovascular disease.
The intestine also contributes to energy homeostasis through
he absorption, metabolism, and transfer of nutrients to the
rganism [13]. Many studies have shown that an excessive post-
randial accumulation of triglyceride-rich lipoproteins (TRL)
n plasma is a risk factor for cardiovascular diseases [14].
nterocytes ensure the transfer of dietary lipids to the organ-
sm through complex processes [15]. In the intestinal lumen,
ietary lipids such as triglycerides (TG) are hydrolyzed into FA
nd monoglycerides, primarily by pancreatic enzymes. The FA
nd monoglycerides associate with biliary secretions and form
ipid micelles, which facilitates their absorption by enterocytes
16]. The FA are taken up by passive diffusion and a protein-
ediated mechanism involving the FA translocate, a FA-binding
rotein from the plasma membrane, as well as the FA transport
rotein family [17]. During the postprandial period, TG are tran-
iently stored in enterocytes as cytosolic lipid droplets; these
re subsequently hydrolyzed and reenter the secretory pathway
18]. Many genes are involved in the control of TG secretion
nd storage. The transcription factor hepatocyte nuclear factor
HNF)-4  is expressed in the liver, pancreas, and intestine [19].
rochot et al. [13] found that postprandial micelles specifically
odulate the expression of 47 genes related to three main func-
ions of enterocytes: cell adhesion/architecture, cell signaling,
nd glucose/lipid metabolism. Of the 47 genes identified, 20,
ncluding apoA-IV, apoB, and MTP, have putative or known
inding sites for HNF-4 [20].
The absorption of lipids not only supplies the nutrition the
ody requires, but also stimulates a number of signaling path-
ays. Recently, Devkota et al. [21] reported that mice fed a diet
ich in milk-derived saturated fat displayed increased liver pro-
uction of taurocholic acid, which in turn stimulated the growth
f certain gut bacteria. In genetically susceptible mice, one such
acterial species, Bilophila  wadsworthia, triggered intestinal
nflammation and colitis.
.3. Peptide  absorption  and  regulationThe transporter PEPT1 is an oligopeptide transporter located
t the intestinal brush border. It is responsible for the trans-
ort of 400 dipeptides and 8000 tripeptides as well as a wide
t
i
o
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ange of peptide-like drugs such as -lactam antibiotics and
ngiotensin-converting enzyme inhibitors [22]. PEPT1 is an H+-
eptide cotransporter that relies on a proton gradient for the
phill transport of peptides that are subsequently transported
cross the basolateral membrane by a facilitative basolateral
eptide transporter [23]. In terms of energetic efficiency, 2 or
 peptides can be transported into a cell by PepT1 for the same
xpenditure of energy as is required to transport a single free
mino acid (AA) [24]. Individuals suffering from deficient free
A transport are still able to assimilate essential AAs, indicating
hat PepT1 can transport enough dietary AAs to compensate for
 deficiency in free AA transport [25]. Transport of AAs in the
orm of peptides has been shown to be a faster route of uptake
er unit time than transport of free AAs [26]. Furthermore, more
As are absorbed by the proximal small intestine when protein is
nfused as a hydrolysate instead of in an intact form, suggesting
hat peptides are more readily available for absorption. Circulat-
ng peptides may not be hydrolyzed in plasma [27]. Peptides are
ikely to be transported into cells and subsequently hydrolyzed
nto free AAs that in turn are used for protein synthesis [28].
he extent of peptide utilization by cells is influenced by dietary
tatus [29]. The above findings suggest that diet influences the
oncentration of circulating peptides. Kim et al. [30] detected
eptidase activity in the brush border and soluble fractions of
at intestinal mucosa targeting 13 dipeptides and 5 tripeptides;
0–90% of the activity occurred in the soluble fractions and
0–15% at the brush border. The peptide transporters are mem-
ers of the proton-coupled oligopeptide transporter superfamily,
hich is also known as the peptide transporter family [24].
eptide transport has been shown to be proton-dependent [31].
himakura et al. [32] proposed a mechanism for the induction
f intestinal PepT1 under fasting or starvation conditions. They
emonstrated that PepT1 induction is mediated by peroxisome
roliferators-activated receptor   (PPAR), a member of a fam-
ly of nuclear receptors activated by FA ligands, and thus plays
n important role in the adaptive response to starvation. The
eptide transporter can be upregulated by insulin, leptin, thy-
oid hormone, T3, and epidermal growth factor [33]. Both the
olecular weight distribution and the concentration of dietary
eptides may influence growth performance and immunologi-
al development. The use of different protein sources, hydrolysis
onditions, and dietary concentrations makes it very difficult to
ompare studies and make any claims regarding efficacy. The
ifferences in the substrate affinity of PepT1 for different pep-
ides, the effect of each peptide on gene expression, and the 8400
ossible di- and tripeptide combinations are all obstacles to the
evelopment of a peptide profile of the digestive enzymes and
ransporters involved in the physiological processes in the gut
34].
For efficient AA and di- and tripeptide absorption, these
rocesses need to be balanced and strictly controlled as well
s coupled with the relevant signaling pathways. Recently,
ashimoto et al. [35] investigated the connection between pro-ein deficiency and intestinal inflammation, and uncovered an
ntricate network involving nutrient transport, microbial ecol-
gy, antimicrobial responses, and inflammation. Tryptophan is
btained from a number of foods and is absorbed in the small
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ntestine by a transporter protein dependent on the enzyme
CE2. Hashimoto et al. demonstrated that mice lacking ACE2
nd those fed a diet lacking tryptophan experienced greater
nflammation in the large intestine in response to damage than
ice with normal tryptophan levels. These deficient mice also
ad reduced levels of intestinal antimicrobial peptides, which
re produced by intestinal epithelial cells. Tryptophan and its
etabolites can, through the action of the transcription-factor
rotein AhR (the aryl hydrocarbon receptor) [36], induce the
roduction of cytokines IL-22 and IL-17 by the intestinal
mmune cells; these then induce greater secretion of antimicro-
ial peptides.
Nutrients are taken up by complex transport systems that
re compactly and stoichiometrically coupled with ion chan-
els, Na+–K+ pumps, sensors, and signaling pathways, and so
he nutrients and their homeostasis must be coordinated with
ntegral physiological, metabolic, immunological, and neuroen-
ocrine systems. As an example, G protein-coupled receptors
GPCRs) encompass the largest and most diverse family of
embrane proteins in eukaryotes. GPCRs transduce a variety
f signals across the cell membrane, sense almost all nutrients,
nd regulate diverse biological and physiological processes. The
unction of GPCRs relies on a specific lipid environment and
s often strongly dependent on the presence of cholesterol and
ons. GPCRs are allosteric machines [37] controlled by ions,
embrane components, and water molecules. This means that
embrane proteins can be controlled not only by dietary lig-
nds, but also by endogenous small molecules located at specific
inding sites. These small molecules can dramatically affect
he stability and function of proteins, which in turn can have
 pronounced effect on the physiological signaling of GPCRs.
ost recently, Liu et al. [38] showed that the central cluster
f such GPCRs harbors a putative sodium ion bound to the
ighly conserved aspartate residue Asp2.50, two cholesterols
tabilize the conformation of helix VI, and one of 23 ordered
ipids intercalates inside the ligand-binding pocket. These high-
esolution details shed light on the potential role of structured
ater molecules, sodium ions, and lipids/cholesterol in GPCR
tabilization and function.
. The  GI  tract  acts  as  an  important  recognition  and
efence system
In the gut, there is a delicate balance between the need to rec-
gnize pathogens and dietary ingredients to prevent unwanted
mmune responses to food antigens or the normal intestinal
ora and the need to simultaneously allow for adequate nutrient
ptake. As the largest area of the GI tract (occupying a surface
rea of almost 400 m2 in man), the gut has developed complex
rotective mechanisms. The mucosal barrier consists of intesti-
al epithelial cells and defence mechanisms such as low pH,
eristalsis, and a mucus coat, all of which protect the intes-
ine from invading or toxic antigens. The intestinal lymphoid
issue is the largest component of the immune system and is
eferred to as the gut-associated lymphoid tissue (GALT). It
onsists of Peyer‘s patches (PPs), mesenteric lymph nodes, iso-
ated lymph follicles, and lymphocytes scattered throughout the
e
I
o
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amina propria and epithelium of the intestine. PPs act as the
rimary inductive sites where the interaction between luminal
ntigens and circulating lymphocytes occurs. The PPs contain
pecialized epithelial cells known as microfold cells (M cells).
 cells are specialized in complete antigen uptake from the
ntestinal lumen and their transport across the mucosal surface
o the subepithelial dome area. M cells are thus fundamental to
ecretory antibody production, vaccination response, and food
llergies.
The antigens are taken up by several antigen-presenting cells
APCs) where they are processed for presentation to T cells in
he PPs. The T cells are activated upon antigen presentation,
nd then differentiate and mature in the germinal centers of the
ollicles. They migrate via  efferent lymphatics to the mesenteric
ymph nodes, and eventually enter circulation. Activated T cells
igrate from the blood to the effector sites of intestinal immune
esponses with the help of adhesion molecules. Here they act as
ffector cells and secret cytokines and mediate specific adaptive
mmune defences [39]. Samples are taken up by the organized
ucous-associated lymphoid tissue (O-MALT), which may also
e present as single lymphoid follicles embedded in aggregated
ollicles such as PPs in the intestine.
.1. The  key  cells  associated  with  information  exchange  in
he mucosa
.1.1.  T  cells
Distinct immune mechanisms have evolved to maintain the
ntegrity of this component of the immune system. T cells
elonging to both the   and   cell lineages are found in
lose physical association with the mucosa. Activated intestinal
 cells, but not   cells, produce the epithelial growth factor
GF-7, suggesting that intestinal   cells and the soluble fac-
ors they produce have important roles in maintaining intestinal
omeostasis in normal and disease conditions [40]. Although a
istinct Th1/Th2 cytokine profile is not as clear in humans as in
nimal cells, there remains an inverse relationship between the
endency of T cells to produce IFN-  as opposed to IL-4 and
L-5 [41]. The synthesis of IL-2, IL-6, IL-10, and IL-13 is not as
ightly restricted to a single subset as in mouse T cells, and both
h classes produce granulocyte-macrophage colony stimulating
actor (GM-CSF), TNF-, and IL-3 [42]. Paliard et al. found that
L-2, IL-4, and IFN- can also been produced in human T-helper
ells [43]. There is a dichotomy between IL-2, IFN-, and TNF-
 versus  IL-4 and IL-5, and therefore the Th1/Th2 dichotomy is
till considered an important functional division in the immune
ystem in  vivo.
.1.2.  Epithelial  cells
The mucosal surface is covered with a single layer of
olarized epithelial cells, which are undifferentiated, actively
roliferating cells. The epithelial cells play important roles in
he uptake and transport of secretory IgA into the lumen. They
xpress a series of cytokines, including IL-1, IL-8, TNF-, and
L-10 [44]. Epithelial cells also express receptors for a variety
f cytokines, such as IL-1R, IL-2R, IL-4R, IL-7R, IL-9R, and
L-15R [45]. In addition, they express MHC class II molecules
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nd have also been shown to be process and present antigens to
rimed T cells. Their expression of adhesion molecules, lym-
hocyte function-associated antigen (LFA), B7, and cytokine
eceptors may trigger a cascade or maintain homeostasis along
he gut. Recently, Mishra et al. [46] demonstrated that Jak3 was
nvolved in IL-2 induced intestinal epithelial cell (IEC) migra-
ion, which is one of the early events in intestinal wound repair.
hey also reported that IL-2 plays a role in IEC homeostasis
hrough concentration-dependent regulation of IEC proliferation
nd cell death by IL-2R.
.1.3.  Macrophages
The GI tract contains the largest number of macrophages
n the body. In addition to their antigen-presenting ability,
acrophages also activate T cells through their production of
ccessory cytokines. Macrophages are more abundant in the
mall intestine. They have been shown to locate in the vil-
ous core, the subepithelial space in crypts, and under the dome
pithelium overlying PPs. Macrophages secrete cytokines such
s IL-1, IFN-, TNF-, IL-8, IL-6, IL-10, and TGF-, and also
xpress receptors for IFN-, IL-4, IL-10, and TNF-. In addi-
ion, they express a number of adhesion and HLA-II molecules.
.1.4.  M  cells
M cells are armed with a series of “take-up” devices.
eceptor-mediated endocytosis and fluid-phase endocytosis
ave both been observed, and M cells also appear to be capable
f transferring immunity from mother to child by phagocytosis.
fter birth, a child’s own immune system is unprimed. He/she
ecomes immune due to the transfer of IgG from the mother by
 cells and the neonatal Fc receptor (FcRn) [47]. In humans, a
imilar process is involved in the transfer of IgA. IgG is secreted
nto the first milk (colostrum) and is transferred across the IECs.
.2. Expression  of  cytokines  and  their  receptors  on  the
ucosa
.2.1. Cytokines  and  receptors
Cytokines are usually classified as proinflammatory (IL-1,
L-2, IL-6, IL-12, IL-18, IFN-, and TNF-), anti-inflammatory
IL-4 and IL-13), or immunosuppressive (IL-10, TGF-) based
n their activity. Epithelial cells also express receptors for a num-
er of cytokines, including IL-1R, IL-2R, IL-4R, IL-7R, IL-9R,
nd IL-15R [45]. These data suggest that there may be a signaling
ascade along the GI tract that is involved in the regulation of
mmunological, physiological, and metabolic activities.
.2.2. Chemokines  and  chemokine  receptors
Chemokines and their receptors are not only involved in the
ontrol of hematopoietic cell migration and the development
f Th1 and Th2, but also in a wide variety of other phys-
ological and pathological processes. Th1 and Th2 cells are
nown to express a variety of surface antigens. Th1 cells pref-
rentially express the CXCR3 and CCR5 chemokine receptors,
hereas Th2 cells express CCR3, CCR4, and CCR8 [48]. The
ey molecules attracting leukocytes to local inflammatory sites
re chemokines. Hannelien et al. [49] undertook a systematic
l
g
fi
pman Wellness 1 (2012) 26–60
eview of the impact of CXC chemokines (binding receptors
XCR1, CXCR2, CXCR3, and CXCR4) on the transition of
hronic inflammation in the upper gastrointestinal tract to neo-
lasia. CXCR2 ligands including GRO-, , /CXCL1, 2, 3,
NA-78/CXCL5, and IL-8/CXCL8 attracted pro-tumoral neu-
rophils. The literature also supports the hypothesis that the
radual change from a controlled immune response to patholog-
cal inflammation and neoplasia in the esophagus and stomach
s partly orchestrated by chemokines. Therapeutic approaches
hat use chemokine receptor antagonists or chemicals target-
ng tumor-promoting chemokines and chemokine receptors may
hus have potential in the prevention and treatment of upper
astrointestinal tract inflammation and tumors.
.2.3. Adhesion  molecules
The migration of lymphocytes in the intestinal mucosa
s a complex multi-step process. It is mediated by adhesion
olecules, the homing receptors of lymphocytes, and counter
eceptors located at the endothelial cells in specialized postcap-
llary high endothelial venules. Different combinations of these
dhesion molecules ensure tissue-specific migration. The selec-
ive recruitment of lymphocytes makes the immune response
ore efficient by directing the cells back to where they first
ncountered their antigen and where they thus are more likely
o meet the specific antigen again [50]. Cells can constitu-
ively express adhesion molecules, and these can be upregulated
y cytokines, chemokines, or other proinflammatory molecules
uch as dietary ingredients or microbial metabolites. In addi-
ion to mediating adhesion, some of these molecules also have
 costimulatory function during intercellular signaling [51].
. Membrane  receptors  expressed  on  the  mucosa
To date, almost all membrane receptors have been observed
n the mucosa, which indicates that these receptors can interact
ith their specific ligands in the GI tract and sense environmental
onditions, especially the nutritional status of the body, via  the
irculatory system.
.1.  G  protein-coupled  receptors  (GPCRs)
G protein-coupled receptors, which are also known as seven-
ransmembrane domain (7TM) receptors, are a large protein
amily involved in the sensing of molecules outside the cell and
nternal activation of multiple signal transduction pathways. The
PCR ligands that bind and activate these receptors include
dors, neurotransmitters, hormones, and molecules ranging
n size from small to large. There are two principal signal
ransduction pathways associated with the G protein-coupled
eceptors: the cAMP signaling pathway and the phosphatidyl-
nositol signaling pathway [52]. There are four major classes
f GPCRs (791 genes): Class A (rhodopsin-like, 662 genes),
lass B (secretin-like, 15 genes), Class C (glutamate receptor-ike, 22 genes) and other (92 genes including Adhesion 33
enes, Frizzled 11 genes, Taste type-2 25 genes, and unclassi-
ed 23 genes.) [53]. The human genome encodes thousands of G
rotein-coupled receptors, about 350 of which detect hormones,
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rowth factors, and other endogenous ligands. Approximately
50 of the GPCRs found in the human genome have unknown
unctions [54].
GPCRs are involved in a wide variety of physiological pro-
esses. Some diet-related roles include: (1) vision. The opsins
se a photoisomerization reaction to translate electromagnetic
adiation into cellular signals. Rhodopsin, for example, uses the
onversion of 11-cis-retinal to all-trans-retinal for this purpose.
his may be used to distinguish food colors; (2) sense of smell.
eceptors of the olfactory epithelium bind odorants (olfactory
eceptors) and pheromones (vomeronasal receptors); (3) nervous
egulation of the GI tract and brain. Receptors in the mammalian
rain bind several different neurotransmitters, including sero-
onin, dopamine, -aminobutyric acid (GABA), and glutamate;
4) autonomic nervous system transmission. Both the sympa-
hetic and parasympathetic nervous systems are regulated by
PCR pathways and are responsible for the control of many
utomatic functions of the body such as appetite and diges-
ion; (5) regulation of the defence system. Chemokine receptors
ind ligands that mediate intercellular communication among
ells, and histamine receptors bind inflammatory mediators and
ngage target cell types in the inflammatory response; (6) bio-
nd chemical sensing of major nutrients such as AAs, sugars,
eptides, nucleotides, and lipids; and (7) homeostasis modula-
ion such as that required to maintain nutrient balance.
The cholecystokinin (CCK) receptors throughout the human
ut have varied physiological functions, evolutionary back-
rounds, and molecular structures. The CCK receptors are
mportant members of the GPCRs as they are involved in the
egulation of many physiological functions such as satiety, GI
otility, gastric acid secretion, gall bladder contraction, pancre-
tic secretion, anxiety, memory, and learning [55].
The GPCRs are activated by a wide variety of external
ignals in the form of ligands or other signal mediators.
hen a ligand interacts with the corresponding receptor,
 conformational change occurs in the receptor, trigger-
ng activation of a G protein. Some receptors for sensory
ignal mediators include olfactory stimulatory molecules;
denosine; GABA; gut-neuroendocrinology signal media-
ors including members of the vasoactive intestinal peptide
amily, vasopressin, platelet-activating factor, neuropeptide
, opioid peptides, somatostatin, tachykinins, and calci-
onin; follicle-stimulating hormone; gonadotropin-releasing
ormone (GnRH); thyrotropin-releasing hormone; dopamine;
pinephrine; norepinephrine; histamine; glutamate; glucagon;
cetylcholine; and serotonin.
Upon receptor activation, the G protein exchanges GDP for
TP, causing the dissociation of the GTP-bound   and /
ubunits and triggering diverse signaling cascades. Receptors
oupled to different heterotrimeric G protein subtypes can uti-
ize different scaffolds to activate the MAPK cascade [56], and
mploy at least three different classes of Tyr kinases. Src family
inases are recruited in turn to activate PI3K  by /  subunits.
hey are also recruited by receptor internalization, and by cross-
ctivation of receptor Tyr kinases. GPCRs can also employ
LC to mediate activation of PKC and Ca2+/Calmodulin-
ependent Protein Kinase II (CaMKII). The Frizzled group
a
c
(
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f GPCRs is evolutionarily conserved and serves to transduce
ignals from the Wnt-type lipoglycoprotein growth factors. G
roteins also play roles in Wnt/Frizzled signaling, as well as in
he identification of other signaling intermediates in intracellular
ignal transduction [57].
Human GPCRs mediate multiple signal transduction path-
ays as well as members of an intricate network of
ntracellular signaling pathways including the cAMP/PKA, cal-
ium/PKC, calcium/nuclear factor of activated T cells (NFAT),
LC, protein tyrosine kinase, PKC/MEK, p43/p44MAP, p38
AP, PI-3 Kinase, NO-cGMP, Rho, NFB, and Jak/Stat
athways [58].
.2.  Pattern-recognition  receptors  (PRRs)
Pattern-recognition receptors (PRRs) are located on various
ell types, including APCs and epithelial cells, and can recognize
icroorganism-associated molecular patterns (MAMPs) such as
ipopolysaccharide (LPS) [59]. They can also enhance attach-
ent and phagocytosis of microorganisms. Toll-like receptor
TLR)-4, the receptor for LPS, mediates bacterial translocation
hrough enterocytes and M cells. Aside from TLRs, epithe-
ial cells also express a variety of mammalian lectins that bind
articular carbohydrates and conjugating carbohydrates on the
urfaces of particles can target these to enterocytes [60].
.3. FcRn  and  immunological  transfer  from  mother  to  baby
The neonatal Fc receptor FcRn was first described in the
ntestine of neonatal rats [61]. Since then, FcRn expression
as been described in many species, including humans. It has
een detected in several tissues including the mammary gland,
ung, placenta, and intestinal epithelium [62]. FcRn binds the
c portion of IgG with high affinity at pH 6.5, but not at phys-
ological pH 7.4 [63]. Several functions ascribed to FcRn are
 direct consequence of this unique pH-dependent IgG bind-
ng: (1) FcRn is involved in the transfer of maternal IgG from
he mother to her offspring to confer short-term passive immu-
ity. This FcRn-mediated IgG transfer occurs through placental
nd/or intestinal pathways depending on species [64]; (2) FcRn
lays an important role as a homeostatic regulator of IgG and
lbumin in adult mammals [65]. Endothelial cells also express
cRn, and endosomal FcRn can bind internalized IgG after
cidification, thereby protecting IgG from lysosomal degra-
ation and thus prolonging its serum half-life to 22 days in
umans [66]. Studies have also demonstrated that FcRn may
lay an important role in mucosal immunity as an immuno-
ogical sensor [67]. It is interesting that FcRn is expressed
n association with the transfer of immunity from adults to
eonates in humans as well as some other species [68]. FcRn
s also expressed in human IEC lines and it transcytoses IgG
olecules bidirectionally across these polarized cell monolay-
rs [69]. The slightly acidic environment of the small intestine
llows FcRn, which is expressed at the apical surface of entero-
ytes, to bind both IgG and antigen-IgG immune complexes
ICs). FcRn then transcytoses these ICs through the epithe-
ial barrier and releases them in the underlying extracellular
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pace. Following transcytosis from the intestinal lumen to the
nderlying GALT, these ICs are endocytosed by CD11+ lam-
na propria dendritic cells (DCs), which then migrate to the
esenteric lymph nodes to activate CD4+ T cells. FcRn can
lso deliver specific IgG to the intestinal lumen, which sub-
equently enhances resistance to intestinal infection [70]. Thus,
cRn clearly has a role in mediating transepithelial transport and
o forms part of an important mechanism by which DCs sam-
le luminal antigens to control for mucosal pathogens. Many of
he functional foods that have been developed are dairy prod-
cts such as immune milk and IgG-fortified milk powder, and
he mechanism of the bioactivity of these products is based on
cRs.
.4. Fibroblast  growth  factor  receptors  (FGFRs)
Fibroblast growth factors (FGFs) act through their cognate
eceptors (FGFRs) and play vital roles in the development
nd regulation of FGF/FGFR signaling, which is associated
ith a number of different syndromes. There is much interest
n the inhibition of FGF/FGFR signaling as a cancer therapy
s FGF/FGFR signaling is important in tumor angiogenesis.
hus, FGFRs are increasingly attractive targets for therapeu-
ic intervention. Knights et al. [71] reviewed FGFR signaling
nd described advances in cancer genomics and cancer cell
iology. FGFs can elicit numerous cellular and physiological
esponses in the human gut, and they have been implicated in
rocesses that include proliferation, differentiation, and angio-
enesis. FGF1–FGF10 and FGF16–FGF23 mediate these effects
y binding to a family of five structurally related receptor
yrosine kinases (RTKs), which are designated FGF receptors
FGFR1–5) [72].
.5.  The  Notch  receptors
The Notch receptors are single-pass transmembrane pro-
eins that are activated by the Delta-like and Jagged families of
embrane-bound ligands. Notch proteins are transported to the
lasma membrane and form matured heterodimers on the cell
urface. Interaction with ligands leads to two additional pro-
eolytic cleavages that liberate the Notch intracellular domain
NICD) from the plasma membrane [73]. Notch was initially dis-
overed to be responsible for the specific phenotype of ‘notches’
n the wing blades of Drosophila  melanogaster  [74]. In mam-
als, the Notch family includes four receptors (Notch1–4).
otch signaling promotes the maturation of both the CD4+
nd CD8+ single positive thymocytes. The Notch receptors can
e glycosylated extracellularly at EGF-like repeats. Notch1 has
een implicated in the determination of T cell fate and in the mat-
ration of early T cells in the thymus [75]. Reedijk et al. [76]
uggested that expression of Jagged ligands and Notch1 and
otch receptor activation are constant features of human colonancers, and thus the application of anti-Notch therapeutics
ay benefit patients with this disease. Notch signaling inter-
cts with many other pathways including PI3K/Akt, NF-kB and
TAT3.
a
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.6.  Glucagon-like  peptide-1  (GLP-1)  receptors
Obesity is prevalent worldwide, but in the USA alone it
as increased by 75% since the early 1980s with more than
ne-third of adults now classified as obese. A number of stud-
es have described the physiological roles of GLP-1 and its
eceptor in the regulation of glucose homeostasis and energy
etabolism [77]. Willard and Sloop [78] reviewed GLP-1 recep-
or physiology with an emphasis on GLP-1-inducing signaling
echanisms in order to highlight new molecular strategies
or guiding development of GLP-1 receptor activators. Glu-
ose and other macronutrients present in a mixed meal, such
s AAs and lipids, are transported to the lumen and stimu-
ate a similar incretin response [79]. In the intestine, nutrients
nteract with their sensory receptors, membrane channel and
ransporter proteins on the membrane surface of open-type
ndocrine cells. These cells release the incretins upon nutri-
nt stimulation. In L cells, which are located throughout the
ntestine, GLP-1 is produced by posttranslational cleavage of
 160 AA proglucaon precursor protein, a process requir-
ng prohormone convertase-1/3 [80]. GIP is a single peptide
erived from proteolytic processing of a 153 AA precursor
rotein expressed in endocrine K cells, which are located
ainly in the duodenum and the proximal jejunum of the upper
mall intestine [81]. When released into circulation, GLP-1
nd GIP facilitate glucose disposal by acting on pancreatic
slets and enhancing postprandial insulin secretion [82]. This
rocess is mediated by heterotrimeric GPCRs. These signals
ccur in response to binding by GLP-1 and GIP, respectively
83].
In humans, the incretin effect is often reduced in patients
uffering from type 2 diabetes mellitus [84]. In contrast to
IP, GLP-1 also induces several additional antidiabetic effects,
ncluding inhibition of glucagon secretion and gastric empty-
ng, which both help improve postprandial glucose control and
ecrease appetite and food intake [85,86]. These effects are
ediated by the GLP-1 receptors expressed in extrapancreatic
issues, most notably those of the GI tract.
Early reports highlighted the ability of the GLP-1 receptor
o couple with alternative signaling pathways, including phos-
holipase C (PLC), and the mobilization of intracellular Ca2+,
hich is consistent with the known ability of GLP-1 to stim-
late Ca2+ mobilization in -cells [87]. Furthermore, many
eports have shown that the GLP-1 receptor is coupled with
a2+ mobilization when heterologously expressed [88]. GLP-1
eceptor stimulation has also been shown to induce biphasic acti-
ation of ERK [89]. This effect includes initial cAMP-dependent
ransient activation of ERK followed by prolonged -arrestin-
-dependent activation of ERK. Translation of this finding to
he GLP-1 receptor identified an analogous peptide, 63Asn-Arg-
hr-Phe-Asp67, as a low potency but fully efficacious GLP-1
eceptor agonist [90]. It is clear that the GLP-1/GLP-1 recep-
or axis is a key physiologic regulator of glucose metabolism,
nd diabetic patients treated with the degradation-resistant GLP-
 receptor peptide agonists exenatide and liraglutide experience
mproved glucose homeostasis. Therefore, a number of efforts to
dentify orally active small molecule GLP-1 receptor agonists
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re currently underway. Functional foods may thus also have
otential in the treatment of type 2 diabetes mellitus and obesity.
.7. The  aryl  hydrocarbon  receptor  (AhR)  and  nuclear
rythroid-related  factor  2 (Nrf2)
Quinones and their phenolic precursors are ubiquitous in
nimals as well as their environment. They include dietary
olyphenols and tocopherols, medical drugs, and the metabo-
ites of environmental pollutants. Quinones are involved in
iverse biologic processes including metabolism of estrogens
nd catecholamines, detoxification of aromatic hydrocarbons,
nd electron transport [91]. Quinone–quinol redox cycles lead
o oxidative stress, and some quinones are highly toxic arylating
gents that activate pathophysiologic processes such as endo-
lasmic reticulum (ER) stress, inflammation, and cancer [92].
nzyme systems have evolved to detoxify reactive quinines such
s multiple glutathione S-transferases (GSTs), NAD(P)H, and
he quinone oxidoreductases NQO1 and NQO2 [93].
.7.1.  AhR  and  Nrf2  regulating  genes
AhR is the only ligand-activated member of the bHLH/PAS
basic helix-loop-helix/Per-Arnt-Sim) family of transcription
actors [94]. It has many roles in the regulation of sex hor-
ones, inflammation, immunoregulation, and detoxification of
ipophilic endo- and xenobiotics [95]. After ligand binding,
hR translocates into the nucleus, sheds its chaperones, and
ssociates with aryl hydrocarbon receptor nuclear translocator
ARNT). The heterodimer binds to xenobiotic response ele-
ents (XREs) with the consensus sequence TnGCGTG of the
arget genes. In addition to classical ligands, such as aromatic
ydrocarbons, a number of endogenous AhR agonists have
een suggested, including tryptophan metabolites, bilirubin, and
icosanoids [96].
Nrf2 is a member of a subset of bZip transcription factors
nown as the CNC bZip family whose members are major
egulators of antioxidant defense and cell survival [97]. As
ranscription factors, AhR and Nrf2 regulate drug-metabolizing
nzyme (DME) genes involved in endo- and xenobiotic detox-
fication and antioxidant defense. AhR and Nrf2 activation is
equired for the expression of Phase II detoxification enzymes.
hese genes have been identified by oligonucleotide microar-
ay analysis in the small intestines of Nrf2-deficient and
ulforaphane-treated mice [98]. AhR and Nrf2 exhibit multilevel
rosstalk: (1) the typical AhR-regulated cytochrome P450A1
CYP1A1) generates reactive oxygen species (ROS) that down-
egulate CYP1A1 expression [99]; (2) Nrf2 has been identified
s a downstream target of AhR based on functional XREs in
he promoter of Nrf2. AhR is also a target of Nrf2 [100]; (3)
oordinate induction of UDP-glucuronosyltransferases by AhR
nd Nrf2 is also possible due to interactions between these two
ranscription factors [101]; and (4) AhR and Nrf2 interact with
ach other in signaling pathways [102]. The regulated genes of
hR and Nrf2 also contain response elements for binding AhR
nd Nrf2 in their cis  elements, including both Phase I and II
etoxifying enzymes, and conjugating enzymes [103]. In one
tudy, normal CYP1A1-induced mice remained healthy when
F
p
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reated orally with benzo[a]pyrene (BaP), whereas enterocyte-
pecific (but not hepatocyte specific) CYP1A1-deficient mice
xperienced fatal bone marrow toxicity and immunosuppression
nder the same conditions [104]. These findings suggest that
fficient detoxification of oral BaP in IECs is achieved by tight
oupling of Phase I and II metabolism. Glucuronides are known
o be released from enterocytes into the intestinal lumen by
he AhR-inducible export transporter breast cancer resistance
rotein BCRP/ABCG2 [105].
AhR has recently become a subject of mainstream immuno-
ogical research and it is set to continue to intrigue with ever
ore complex modes of modulating immune responses [106].
he highly selective expression of AhR on Th17 cells and its role
n the induction of the cytokine IL-22 was suggested as a new
mmunological function of this transcription factor and stimu-
ated further research into the physiological functions of AhR in
he immune system [36]. AhR expression is assumed to be ubiq-
itous in the immune system, an interpretation which is based on
 global microarray analysis of immune cell populations [107].
.7.2. AhR  in  innate  immune  cells
It stands to reason that AhR expression in many innate cells
ould have important implications for the functioning of the
omplex interactions between innate and adaptive immune cells.
urthermore, it is assumed that AhR is widely expressed in
nnate cells such as neutrophils, macrophages, NK cells, and
Cs [108]. Langerhans cells express high levels of AhR and
he absence of AhR results in impaired maturation and antigen-
resenting capacity [109]. AhR expression levels increase in
esponse to TLR ligands, and AhR-deficient DCs are asso-
iated with defective IL-10 production in response to TLR
timuli [110]. One study linked NFB Relb to AhR [111] dur-
ng IL-8 transcription. AhR-mediated derepression of the IL-6
romoter provides an intriguing insight into the mechanism of
hR-mediated modulation of cytokine responses in conjunction
ith NFB components [112]. A reduction in IL-10 production
y DCs and macrophages is likely to boost pro-inflammatory
esponses. Furthermore, the widespread expression of AhR on
pithelial cells can be expected to exert influences on cells of
he immune system, which are in close proximity and engage in
utual interactions in homeostasis and immune responses.
.7.3. AhR  in  adaptive  immune  cells
Exemplified by the issue of AhR expression in regulatory T
Treg) cells. AhR expression in Treg cells is above background
evels when compared with non-activated Th0, Th1, and Th2
ells, but is delayed by a few minutes compared with Th17 cells
36]. The role of AhR in the induction of IL-22 production by
h17 cells and subsets of TCR  T cells indicates that AhR has
 clear function in a subset of immune cells [36]. Some studies
ave also shown that AhR activation contributes to Th17 differ-
ntiation [113]. The combined contribution of IL-6 and TGF
s mandatory before AhR can exert any effects on Th17 cells.
urthermore, it is postulated that Notch signaling promotes the
roduction of endogenous ligands for AhR, which then promotes
L-22 expression [114]. DCs have been shown to affect Treg dif-
erentiation in the intestinal environment via  retinoic acid and
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GF  [115]. Interestingly, AhR-dependent CYP enzymes are
nown to metabolize retinoic acid [116] and may be indirectly
nvolved in the complex interactions and development of T cell
ubsets in the gut.
.7.4.  AhR  and  autoimmunity
AhR has also been suggested as forming the mechanistic
asis for the involvement of environmental triggers in autoim-
une syndrome [117]. Furthermore, the link between AhR and
L-22 production by Th17 cells suggests a potential associa-
ion between this transcription factor and autoimmunity, which
s strongly associated with exacerbated IL-22 responses [118].
his suggests that autoimmune syndromes may be triggered by
he interaction of environmental factors with AhR [119]. AhR
gonists have also been suggested for the treatment of autoim-
une diseases [120]. Hopefully further research will establish
 firmer basis to justify the undertaking of clinical trials of
hR agonists or antagonists for the treatment of autoimmune
isorders as well as for producing foodstuffs without allergens.
.7.5. Ahr  and  Nrf2  associations  with  phytochemicals
AhR and Nrf2 regulating genes/enzymes are attractive since
hey can be modulated by, for example, phytochemicals. Phyto-
hemicals can be both activators and inhibitors of AhR and Nrf2,
nd include resveratrol, sulforaphane, and epigallocatechin gal-
ate [121]. Notably, Nrf2 activation by phytochemicals follows
 biphasic dose-response relationship: a stimulatory effect at a
ow dose is followed by adverse responses at higher doses [122].
hus, the effects of functional foods on health may be evaluated
sing these receptors. We may boldly speculate that at least some
f Chinese herbal medicines function by interacting with these
eceptors.
.8. The  R3  subtype  of  receptor-type  protein  tyrosine
hosphatases
The R3 subtype of receptor-type protein tyrosine phos-
hatases (RPTPs) includes vascular endothelial tyrosine
hosphatase (VE-PTP), density-enhanced protein tyrosine phos-
hatases (DEP)-1, protein tyrosine phosphatase receptor type O
PTPRO), and stomach cancer-associated protein tyrosine phos-
hatase (SAP)-1. These enzymes share a similar structure with
 single catalytic domain and putative tyrosine phosphoryla-
ion sites in the cytoplasmic region and fibronectin type III-like
omains in the extracellular region. SAP-1 of the receptors is
ocated on gastrointestinal epithelial cells. In addition, these
PTPs are localized specifically at the apical surfaces of polar-
zed cells. The structure, expression, and localization of the R3
PTPs suggest that they perform tissue-specific functions and
ight act through a common mechanism including activation of
rc family kinases [123]. Protein tyrosine phosphatases (PTPs)
re thought to play important roles in proliferation, differenti-
tion, and migration [124]. These enzymes are also important
egulators in the central nervous system, the immune system,
nd in many organs. Deregulation of PTPs is associated with
arious disorders, and so many members of the PTP family
re considered potential therapeutic targets [125]. The human
m
h
f
bman Wellness 1 (2012) 26–60
enome encodes 107 PTPs, of which the class I cysteine-based
TPs form the largest group. These are further divided into
8 tyrosine-specific PTPs and 61 dual-specific phosphatases
126]. SAP-1 was originally identified as a PTP expressed in
 human stomach cancer cell line, and its expression is largely
estricted to the GI tract [127]. In particular, SAP-1 localizes to
he microvilli of the brush border of the small intestine and colon
s well as to the stomach. The predominant expression of SAP-
 in gastrointestinal epithelial cells and its localization to the
icrovilli of these cells suggest that SAP-1 might play a role in
he maintenance of the microvillus architecture. Forced expres-
ion of SAP-1 was shown to inhibit the proliferation of cultured
ells through attenuation of growth factor-induced activation of
APK or through induction of caspase-dependent apoptosis
128]. SAP-1 likely also promotes intestinal cell proliferation
hrough activation of the Src family of protein tyrosine kinases
SFKs). A more complete understanding of the physiological
unctions of R3 RPTPs, as well as the identification of their lig-
nds, may provide a basis for the development of new functional
oods or medicines for a variety of medical disorders, including
ancer.
.9. Toll-like  receptors  (TLRs)
TLRs play a critical role in the innate immune response to
nvading pathogens by sensing microorganisms and endoge-
ous danger signals, including those associated with a variety
f food chemicals. TLRs are evolutionarily conserved recep-
ors, and are homologues of the Drosophila  Toll protein; they
re known to be important for defense against microbial infec-
ion [129]. TLRs recognize highly conserved structural motifs
nown as pathogen-associated microbial patterns (PAMPs),
hich are exclusively expressed by microbial pathogens, or
anger-associated molecular patterns (DAMPs). Stimulation of
LRs by PAMPs or DAMPs triggers signaling cascades that acti-
ate transcription factors such as NF-B, AP-1, and interferon
egulatory factors (IRFs). Signaling by TLRs may result in a
ariety of cellular responses including the production of pro-
nflammatory cytokines, chemokines, interferons (IFNs), and
ffector cytokines that direct the adaptive immune response.
The TLR family of type I trans-membrane proteins is char-
cterized by an extracellular domain containing leucine-rich
epeats (LRRs) and a cytoplasmic tail that contains a con-
erved region—the Toll/IL-1 receptor (TIR) domain. TLRs are
redominantly expressed in tissues involved in immune func-
ion, peripheral blood leukocytes, and in the lungs and GI tract.
en human TLRs have been characterized to date: TLR1–10.
LR2 is essential for the recognition of a variety of PAMPs
rom Gram-positive bacteria, including bacterial lipoteichoic
cids, lipomannans, and lipoproteins. TLR3 recognizes virus-
erived double-stranded RNA. TLR4 is activated by LPS and
LR5 detects bacterial flagellin. TLR9 is a sensor for unmethy-
ated CpG DNA, and TLR7 and TLR8 identify small antiviral
olecules and single-stranded RNA [130]. Significant progress
as been made over the past few years in understanding TLR
unction [131]. It is well known that many foods are fermented
y various microorganisms, and some foods are themselves
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ormed by macrofungi. It appears inevitable then that ligands
nd their TLR agonists will be present in these foods. How
an we deal with this problem? It is believed that our bod-
es have evolved a mechanism to restrict homeostatic signaling
ystems, just as the TLR7 versus  TLR9 balance has been iden-
ified as a mechanism for tightly controlling expression and
ctivation of the RNA-sensor TLR7 by downstream signaling
athways [132].
.10.  Opioid  receptors  in  the  GI  tract
Opioid receptors belong to the family of seven trans-
embrane GPCRs with 50–70% homology between their
oding sequences [133]. Opioid receptors couple via  the Gi/Go
ubtypes of G proteins to cellular transduction processes. Once
ctivated by agonists, -opioid receptors undergo endocyto-
is in a concentration-dependent manner [134]. The signaling
athways of opioid receptors are well characterized. Their
ffects mirror the actions of the endogenous opioid system,
nd are mediated by the principal -, -, and -opioid recep-
ors. In the gut, met-enkephalin, leu-enkephalin, -endorphin,
nd dynorphin occur in both neurons and endocrine cells.
hen released, opioid peptides activate opioid receptors on
he enteric circuitry controlling motility and secretion. These
rocesses increase sphincter tone, induce stationary motor pat-
erns, inhibit gastric emptying, and blockade of peristalsis ensues
135]. The endogenous ligands of opioid receptors are derived
rom three independent genes, and their appropriate processing
ields the major representative opioid peptides -endorphin,
et-enkephalin, leu-enkephalin, and dynorphin. These peptides
nd their derivatives exhibit different affinities and selectivities
or the -, - and -receptors located on the central and periph-
ral neurons, mucosal cells, neuroendocrine, and immune cells,
mong others [136].
Hughes et al. identified leucine-enkephalin and methionine-
nkephalin as the first endogenous opioid receptor agonists
137]. These pentapeptides were also found in the gut [138].
ubsequent analysis of their function revealed that opioid recep-
or agonists interact with pathways of the enteric nervous system
hat regulate GI motility and secretion [139]. There is evidence
hat some effects of opioid receptor agonists in the GI tract may
e mediated by opioid receptors in the brain [140]. Many neu-
oactive drugs act on the gut because the alimentary canal is
quipped with the largest collection of neurons outside of the
rain. Enteric neurons originating from submucosal plexuses
upply all layers of the alimentary canal, and are thus are in
 position to regulate digestion [141]. Enteric neurons synthe-
ize and release acetylcholine, nitric oxide, vasoactive intestinal
olypeptide, ATP, substance P, and 5-hydroxytryptamine, as
ell as their opioid peptide transmitters. This may explain
hy exogenous opioid analgesics inhibit GI function. Met-
nkephalin, leu-enkephalin, -endorphin, and dynorphin have
een localized to both enteric neurons and mucosal endocrine
ells [142]. The -, -, and -subtype opioid receptors have
een localized to the GI tract of humans [143]. In the human
ut, -opioid receptors are present on myenteric and submu-
osal neurons as well as on immune cells in the lamina propria
f
o
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134]. The cellular effects of myenteric -opioid receptor acti-
ation are brought about by multiple transduction pathways
ncluding membrane hyperpolarization, inhibition of calcium
hannels, activation of potassium channels, and reduced pro-
uction of cAMP [144]. Studies show that -, -, and -opioid
eceptors of the human intestine contribute to opioid-induced
nhibition of muscle activity. Evidence indicates that opioid-
nduced inhibition of GI transit is mediated by opioid receptors
n the gut, and also that opioids acting within the brain also
nfluence GI function. The ability of opioid receptor agonists
o inhibit GI secretory activity and transit are therapeutically
xploited for the treatment of acute and chronic diarrhea as well
s irritable bowel syndrome-associated diarrhea [145]. Periph-
rally restricted opioid receptor antagonists may thus be able to
ormalize the pathological inhibition of gut function that arises
rom upregulation and/or overactivity of the opioid system in the
I tract [146]. The development of opioid receptor antagonists
ith restricted access to the central nervous system has opened
p a new way to prevent the undesired effects of opioid anal-
esics outside the central nervous system [135]. These receptors
lso provide us with a series of targets against which to screen
ifferent agonists and antagonists in medicines or functional
oods and determine their therapeutic activity for numerous dis-
ases of the central nervous system, GI tract, immune system, the
espiratory system, and other disorders related to inflammation,
lcoholism, binge eating, and obesity [136].
.11. Nuclear  receptors  of  the  enteric  tract
Nuclear receptors are a class of proteins found within cells
esponsible for sensing steroid and thyroid hormones as well
s many other molecules. They work with other proteins to
ontrol the expression of specific genes to control homeosta-
is and metabolism. Nuclear receptors can bind directly to
NA and regulate gene expression. They are thus classified
s transcription factors [147]. The nuclear receptor superfa-
ily comprises 48 ligand-activated transcription factors that
ave been grouped on the basis of shared structural features
148]. The ligands of nuclear receptors include lipophilic sub-
tances such as endogenous hormones, vitamin A, vitamin D,
nd xenobiotics, among others. Many of these genes are asso-
iated with health and the molecular targets of approximately
3% of U.S. Food and Drug Administration (FDA)-approved
rugs are nuclear receptors [149]. Nuclear receptors typically
ind DNA as either homodimers or heterodimers. The retinoid
 receptors (RXRs) are obligate heterodimer partners, which
eans that all nuclear receptor heterodimers must include one
f the RXRs. The nuclear receptor superfamily can be subdi-
ided into 4 groups based on the type of ligand bound and the
NA binding mechanism. The first of these classes includes
he endocrine receptors that bind DNA as homodimers. These
nclude the estrogen, androgen, glucocorticoid, mineralocorti-
oid, and progesterone receptors. The second group of receptors
orm heterodimers with RXRs and are activated by a wide range
f dietary lipids including FAs (bind PPARs), bile acids (bind
XR), xenobiotics (bind PXR, CAR), and a variety of cholesterol
etabolites referred to as oxysterols (bind LXRs). The metabolic
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eceptors activate transcriptional programs to turn on catabolic
athways for dietary lipids. The third group comprises retinoic
cid (vitamin A), 1, 25-dihydroxyvitamin D3, and thyroid
ormone receptors. These also function as RXR heterodimers,
ut their ligands are synthesized in the body from precursors
hat are derived from the diet. The final group includes recep-
ors with no known ligands, which are referred to as orphan
uclear receptors [150].
These orphan receptors [151] have unknown endogenous lig-
nds. Some, such as farnesoid X receptor (FXR), liver X receptor
LXR), and peroxisome proliferator-activated receptors (PPARs,
 types of PPARs have been identified: , , and ()) bind
 number of metabolic intermediates such as FAs, bile acids,
nd/or sterols with relatively low affinity. These receptors may
hus function as metabolic sensors. Other nuclear receptors,
uch as constitutive androstane receptor (CAR) and pregnane
 receptor (PXR), appear to function as xenobiotic sensors by
pregulating the expression of cytochrome P450 enzymes that
etabolize these xenobiotics [152]. The major functions of the
nteric nuclear receptors, namely the vitamin D receptor (VDR),
he bile acid receptor (FXR), and the xenobiotic receptors (PXR
nd CAR), are summarized below.
1) Absorption of beneficial nutrients and maintenance of
homeostasis. Although it is well known that VDR reg-
ulates mineral homeostasis, probably the most important
site of VDR action is in the intestine. Here, the transcrip-
tional regulation of ion channels and transport proteins
by VDR is essential for the uptake of calcium. Insuffi-
cient calcium absorption is the primary cause of decreased
bone mineralization resulting from a loss of VDR activ-
ity [153]. In the intestine, VDR directly regulates calcium
transport and binding proteins. It has become clear that the
calcium-sensing receptor (CaSR) has a number of important
functions because of its ability to activate many differ-
ent signaling pathways. This means that the receptor has
a number of different but crucial roles in human health.
Recently, Ward et al. [154] emphasized that the CaSR may
have multiple roles not only in disorders associated with
calcium homeostasis, but also in unrelated diseases, such as
colorectal cancer, Alzheimer’s disease, diabetes mellitus,
hypertension, and GI disorders, because of its involvement
in so many signaling pathways. The traditional role of bile
acids is simply to facilitate the absorption and digestion of
lipid nutrients, but bile acids also act as endocrine signaling
molecules that activate nuclear and membrane receptors to
control integrative metabolism and energy balance. Recent
evidence has shown that transcriptional cofactors sense
metabolic changes and modulate gene transcription by
mediating reversible epigenomic post-translational modi-
fications (PTMs) of histones and chromatin. Importantly,
targeting these epigenomic changes has been a successful
approach for treating human diseases. Smith et al. [155]
reviewed the roles of transcriptional cofactors in the epige-
nomic regulation of metabolism, and focused on bile acid
metabolism in particular. Targeting PTMs of histones and
chromatin remodelers together with the bile acid-activatedman Wellness 1 (2012) 26–60
receptors may provide new therapeutic options for bile acid-
related diseases such as obesity and diabetes.
2) Elimination of toxic compounds. Although only a subset of
the enteric nuclear receptors regulates nutrient absorption,
they all play a role in the elimination of toxic substances,
drugs, and xenobiotics absorbed by the gut. As xenobio-
tic sensors, PXR and CAR are the principle modulators
of detoxifying pathways involving phase I, II, and III
enzymes and transporters. While the liver is the major
organ associated with bile acid and xenobiotic metabolism,
it is now known that the intestine expresses many of the
same enzymes and contributes to the metabolism of orally
ingested foodstuffs and drugs/xenobiotics in the lumen.
A number of studies have focused on the transcriptional
targets and drug metabolizing roles of nuclear receptors
such as PXR, CAR, and FXR, particularly with respect
to drug interactions and metabolism, and it is likely that
these evolved to protect the body from toxins. In the first
phase of drug/xenobiotic metabolism, a substrate is typically
modified through the addition of a hydroxyl group by the
cytochrome P450 (CYP) superfamily. The reactions carried
out by this family of monooxygenases include oxidation,
reduction, and hydrolysis. In phase II, the chemicals are
further modified by conjugating enzymes that add a larger,
more hydrophilic group such as glutathione, glucuronic
acid, taurine, or acetate. Phase III involves the transport of
the modified and water-soluble compounds out of the cells.
All components of this system are under transcriptional reg-
ulation by the enteric nuclear receptors: VDR, PXR, FXR,
and CAR. These four nuclear receptors act as the sensors of
the intestinal detoxifying system, and thus have the impor-
tant role of activating the effectors protecting enterocytes
from dietary toxins. Enterocytes express many members
of the two major classes of membrane transporters, the
ABC transporters and the solute carrier (SLC) transporters.
Both are regulated by PXR, whereas multidrug resistance-
associated proteins-2 (MRP2) is also regulated by CAR
[156,157]. Since the ion pumps are located in the apical
membranes of the enterocytes, they return toxic compounds
directly to the gut lumen [158].
3) Protection of the gut against pathogens. The enteric tract
is host to a large microbial community. In addition to the
mucosal barrier formed by tight junctions between epithe-
lial cells and mucus, gastric acid, pancreatic juices, biliary
secretions, secretory IgA, and antimicrobial peptides form
the major mucosal defense arsenal. It is well known that
bile acids are toxic to microbes. The microbicidal activ-
ities of steroids also have intrinsic detergent properties.
Research has shown that the antimicrobial activity of bile
acids can be mediated, in part, by their activation of FXR
in the intestine [159]. This discovery was made from a
genome-wide survey of FXR targets in the intestine that
identified a group of genes involved in innate mucosal
immunity. VDR is also expressed in cells of the adaptive
immune system, and vitamin D has been shown to prevent
or reduce autoimmune disease [160]. Vitamin D inhibits
the activation of T cells, and promotes tolerance in DCs
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[161]. VDR has also been implicated in TLR signaling
and in the regulation of the innate immune response in
macrophages [162]. Recently, Agace and Persson [163]
published a review of vitamin A metabolism in DCs gener-
ated in the gut mucosa. They reported that several mediators
directly induce vitamin A metabolism in DCs, including cer-
tain TLR ligands, cytokines, PPAR  ligands, and RA itself.
The small intestine and mesenteric lymph nodes (MLNs)
contain higher concentrations of retinol than other tissues,
including the colon, as a result of dietary intake and prob-
ably also bile secretion. This in turn leads to enhanced RA
generation and signaling in the small intestine environment,
and offers a likely explanation for the efficient imprinting of
small intestine DCs (SIDCs) compared with DCs in other
tissues.
4) Control of proliferation, differentiation, and carcinogene-
sis. Diets high in animal fats are believed to increase the
risk of colon cancer by elevating levels of fecal bile acids.
A unifying hypothesis to explain the effect of VDR and
bile acids on tumor promotion was proposed when it was
discovered that VDR is activated by the toxic secondary
bile acid lithocholic acid (LCA) [164]. In a normal diet,
LCA levels are low and circulating vitamin D can prime
the system to ensure a basal level of catabolic activity.
In a high-fat diet and/or in a vitamin D-deficient state,
the rate of LCA metabolism is inadequate, and so LCA
builds up to toxic levels, damages the colonic epithe-
lium and causes cancer [165]. Like VDR, other enteric
nuclear receptor groups could have direct effects on pro-
liferation/differentiation as well as indirect effects such as
the detoxification of carcinogens or reduction of oxidative
stress.
5) Endocrine regulation of enteric nuclear receptors. Recent
discoveries have focused on transcriptional regulation of a
subfamily of FGFs. Most FGF signals act in an autocrine
or paracrine fashion, However, members of the FGF19
subfamily are released into circulation and function as
endocrine hormones [166]. FXR controls the synthesis of
FGF19, which signals in an intestine-liver and intestine-
gallbladder axis to regulate bile acid synthesis and secretion.
Regulation of secreted FGF19 and FGF23 led to the dis-
covery of a third member of this subfamily—FGF21, a
fasting hormone regulated by the FA receptor PPAR
[167]. These discoveries have drawn attention to the impor-
tance of enteric nuclear receptor signaling not only within
the intestine, but also in the coordination of complex
multi-organ physiological processes. More recently, Jakob-
sson et al. [168] discussed our current understanding of
LXR biology and pharmacology with an emphasis on the
molecular aspects of LXR signaling that constitute the
potential of LXRs as drug targets. They suggested that the
recent discoveries of LXR-regulated pathways in inflam-
mation and proliferation have ignited interest in LXRs as
drug targets for metabolic, chronic inflammatory, and neu-
rodegenerative disorders. This means that successful drug
development must focus on limiting the range of LXR
signaling.
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.12.  The  transient  receptor  potential  vanilloid  1
The transient receptor potential (TRP) channels are a fam-
ly of ion channels that sense stimuli from chemical substances.
ost TRP channels include 6 membrane-spanning helices and
re expressed in many tissues and organs. TRPs have been sub-
ivided into 6 main subclasses based on their ligands: TRPC,
RPV, TRPM, TRPP, TRPML, and TRPA [169]. The transient
eceptor potential vanilloid (TRPV) 1, also known as capsaicin
eceptor due to its sensitivity to capsaicin, is an ion channel that is
redominantly expressed in sensory nerves [170]. TRPV1 has
een found to be widely distributed in a number of different
issues and organs [171], and its effects on health and disease
ave been investigated. As an ion channel, it is able to sense a
eries of stimuli and triggers multiple signaling pathways. It has
een shown that endogenous arachidonic acid derivatives and
ypoxygenase products exert a highly potent stimulatory effect
n TRPV1 [172]. The FA amide arachidonylethanolamide, also
nown as anandamide, is known as a cannabinoid receptor 1
CB1) agonist. TRPV1 is highly sensitive to capsaicin, which
s an exogenous agonist of TRPV1 [173]. Rutaecarpine has
xtensive pharmacological actions from beneficial effects on GI
unctions to anti-inflammatory and anti-obesity effects [174].
vidence suggests that TRPV1 is involved in many other phys-
ological or pathophysiological processes: (1) it takes part in
he regulation of appetite and body weight [175]; (2) it plays
 role in body temperature maintenance [176]; and (3) TRPV1
lso has effects on GI and cardiovascular systems due to the
ctivities of its agonists [177]. Jun et al. discussed the role of
RPV1 in pain signaling, body temperature maintenance, fat
istribution, and respiratory inflammation in their review [178].
 number of TRPV1 blockers have been developed, and some
re in clinical trials [179]. It is obvious that TRPV1 is a useful
arget when searching for active constituents of functional foods
r medicines for the treatment of various diseases including GI
isorders.
There are many other receptors involved in GI systems,
ncluding lactoferrin receptors (LfR) [180], somatostatin recep-
ors [181], histamine receptors (the latter two belong to the
hodopsin-like family of GPCRs) [182], seven-transmembrane
eceptors [183], and chemokines and their receptors [184]. We
ocused on the receptors briefly introduced above because these
re, in our opinion, the main receptors of importance for func-
ional foods.
. Interactions  between  the  gut  microbiota  and  dietary
utrients
Prebiotics, polyunsaturated fatty acids (PUFAs), and phy-
ochemicals are the most well-characterized dietary bioactive
ompounds. The beneficial effects of probiotics mainly relay
n their influence on the composition of the gut microbiota
nd their ability to generate fermentation products with numer-
us bioactive roles. PUFAs include the -3 and -6 FAs, the
alance of which may influence diverse aspects of immunity
nd metabolism [185]. Moreover, interactions between PUFAs
nd components of the gut microbiota may also influence their
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iological roles. Phytochemicals are bioactive non-nutrient plant
ompounds that are of interest because of their anti-estrogenic,
nti-inflammatory, immunomodulatory, and anticarcinogenic
ffects. However, the bioavailability and effects of polyphenols
s very dependent on their transformation by components of
he gut microbiota. Prebiotics are mainly non-digestible food
ngredients, mostly oligosaccharides, that beneficially affect the
ost by stimulating the activity of specific intestinal bacte-
ia. Possible beneficial effects of prebiotics include the control
f intestinal transit and bowel habits, and a reduction in the
isk of obesity, atherosclerosis, type 2 diabetes, and allergies,
lthough their effectiveness in humans remains controversial
186]. Galacto-oligosaccharide (GOS) and inulin-derivatives
e.g., fructo-oligosaccharide) are prebiotics that have been com-
ercialized in Europe. GOS is a non-digestible oligosaccharide
erived from lactose that is found naturally in human milk and
onsists of chains of galactose monomers. Consumption of this
robiotic may increase the total amount of bifidobacteria in
he gut [187]. Inulin and its hydrolytic product (oligofructose)
re fructans that are linked by different numbers of fructose
onomers. These occur naturally at high concentrations in plant
oods such as asparagus and wheat, and have different func-
ions, including the induction of anti-inflammatory effects and
he regulation of lipid and glucose metabolism [187].
The effects of these prebiotics on immune functioning may
e due to their impact on the gut microbiota and the generation
f short-chain fatty acids (SCFAs) by binding to SCFA recep-
ors [188]. SCFAs may also regulate intestinal fat absorption as
utyrate, for instance, impairs lipid transport [189]. Inulin and
nulin-type fructans are soluble fibers that can modulate the gas-
ric emptying and intestinal transit time, delaying absorption of
lucose and improving glucose metabolism [190]. Furthermore,
ietary fibers including some non-digested polysaccharides such
s chitins, pectins, beta-glucans, and lignin can modulate the
ransit time through the gut.
Recently, Haiser and Turnbaugh [191] reported that the
ut microbiota interact with xenobiotics directly by catalyzing
arious biotransformations. In turn, many xenobiotics inhibit
icrobial growth. Indirect interactions are also ubiquitous,
ncluding microbial effects on the expression and activity of
omponents of host xenobiotic metabolism. Multiple studies
ave provided a wealth of information by elucidating the rates
f absorption, distribution, metabolism, and excretion of xeno-
iotics including therapeutic drugs, antibiotics, and diet-derived
ioactive compounds [192].
A neglected but critical component of xenobiotic metabolism
s the influence of the trillions of microorganisms that inhabit our
astrointestinal tract. Members of the gut microbiota can also
nfluence xenobiotic metabolism by altering host gene expres-
ion and producing compounds that interfere with metabolism
utside of the gut [193]. A review of the pharmacological
iterature revealed several cases in which a particular biotrans-
ormation was suspected to result directly from a reaction
arried out by gut microbes [194]. The gut microbiome also
ffects the metabolism of food-derived bioactive compounds. A
etabolomic screen of human plasma revealed that the phos-
hatidylcholine metabolites choline, trimethylamine N-oxide,
e
e
c
fman Wellness 1 (2012) 26–60
nd betaine serve as predictive biomarkers for the development
f cardiovascular disease [195]. These findings highlight the
ritical role of the gut microbiota in metabolism and also serve
s an example of how the composition of commensal microbial
ommunities can directly affect our health.
.1. Host-microbiota  metabolic  interactions  in  the  gut
More recently, Nicholson et al. published a review in Sci-
nce [196] where they emphasized that the influence of the gut
icrobiota on human health is continuous from birth to old age.
he maternal microbiota may also influence both the intrauter-
ne environment and the postnatal health of the fetus. At birth,
bout 100 microbial species populate the colon. Early environ-
ental factors, nutritional factors, and epigenetic factors have
een implicated in the composition of the gut microbial sym-
iont community. Gut microbial composition in early life can
nfluence the risk for developing diseases in later life. Shifts of
icrobial diversity occur along with the transition from child-
ood to adult life. There is a decrease in Bacteroidetes  and
n increase in Firmicutes. The gut microbiota are important
or maintaining normal physiology and for energy production
hroughout life. Body temperature regulation, reproduction, and
issue growth are energy-dependent processes that may partly
epend on microbial energy production in the gut. Extrinsic
nvironmental factors and the host genome influence the diver-
ity and function of the gut microbiota and health. Disruption
f the gut microbiota can lead to diseases including inflam-
atory bowel disease, colon cancer, irritable bowel syndrome,
on-alcoholic fatty liver disease, obesity, metabolic syndromes,
nd hypertension, among others.
The gut microbiota are involved in the regulation of a
umber of host metabolic pathways, giving rise to interac-
ive host-microbiota metabolic, signaling, and immune axes
hat physiologically connect the gut, liver, muscles, and brain.
rosstalk between the microbes and the host immune system is
ransmitted through a series of signaling pathways beyond the
mmune system. These signaling processes, together with direct
etabolic interactions between the microbe and host, act upon
he gut, liver, and nervous system. These interactions consti-
ute a complex host-microbe metabolic network. The host and
ts gut microbiota coproduce a large array of small molecules
uring the metabolism of food and xenobiotics, many of which
lay critical roles in shuttling information between host cells.
ietary fiber can be digested and subsequently fermented in the
olon by gut microbes into SCFAs such as butyrate, propionate,
nd acetate, and are sensed by the GPCRs GPR41 and GPR43,
hich are expressed by gut enteroendocrine cells [197]. Butyrate
as been shown to regulate energy homeostasis by stimulating
eptin production in adipocytes and by inducing glucagon-
ike peptide-1 secretion by the intestinal enteroendocrine L
ells [197]. Butyrate regulates neutrophil function, induces
xpression of vascular cell adhesion molecule-1, increases the
xpression of tight junction proteins in the colon epithelia, and
xhibits anti-inflammatory effects by reducing cytokine and
hemokine release. SCFAs have been reported to regulate the
unction of histone deacetylases and to stimulate the sympathetic
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ervous system [198]. SCFAs have also been shown to stimulate
ut motility and intestinal transit at physiological concentra-
ions, which have been shown to induce multi-fold increase in
erotonin release [199]. The colonization of a germ-free mouse
ith the intestinal microbiota from an obese mouse donor
nduced a body weight gain that was more substantial than when
he microbiota from a lean mouse was transferred [200]. This
esult provided the first insight into the potential contribution
f the microbiota to obesity. Thus, prebiotics can be defined
re nondigestible food substrates that promote the growth of
ntestinal bacteria that confer health benefits on the host.
Another metabolic disease associated with obesity and
etabolic syndrome is nonalcoholic fatty liver disease, which
ccurs in 20–30% of the general population, but in 75–100%
f obese individuals. The intestinal microbiota may contribute
o the development of nonalcoholic fatty liver disease through
omplex cooperation of two microbe-sensing protein families:
ucleotide oligomerization domain receptors (NLRs) and TLRs
201]. These regulate metabolic events through inflammasome
202], and stimulate TLR4 and TLR9, respectively, leading to
ncreased secretion of tumor-necrosis factor TNF-, which in
urn drives progression of nonalcoholic steatohepatitis. Prebi-
tics and other dietary interventions have been shown to have
n obvious effect on the expression of TLRs [203]. The gut
icrobiota may constitute a complex metabolic network of com-
unications between dietary nutrients and the host. Perhaps the
reatest challenge will be to understand the temporal dynamics
f metabolic communication between the host, dietary com-
ounds, and the gut microbiota, and to evaluate the real effects
f functional foods and medicines in  vivo.
.2. Interactions  between  the  microbiota  and  the  immune
ystem
In the lower intestine, the gut microorganisms reach extraor-
inary densities and have evolved to degrade a variety of plant
olysaccharides and other dietary substances [204]. This not
nly enhances host digestive efficiency, but also ensures the
utrient supply for the microbes. These interconnections are
articularly clear in the relationships between the microbiota
nd the immune system. Several immune effectors are used to
imit bacterial–epithelial contact. These include the mucus layer,
ecretory immunoglobulin A (SIgA), and epithelial antibacterial
eptides [205]. These microbes and complex antigens are sam-
led by intestinal DCs. Mature DCs migrate to the mesenteric
ymph nodes through the intestinal lymphatics. This compart-
entalizes live bacteria and the induction of immune responses
n the mucosal immune system. Induced B and T cell subsets
re recirculated through the lymphatics and the bloodstream and
ome back to the mucosa, where B cells differentiate into IgA-
ecreting plasma cells. RegIII  is an antibacterial lectin that
s expressed in epithelial cells under the control of TLRs [206].
egIII  limits bacterial penetration of the small intestinal mucusayer, thus restricting the number of bacteria that contact the
pithelial surface [207]. These mature DCs interact with B and T
ells in the PP, inducing B cells to produce SIgA directed against
ntestinal bacteria [208]. The SIgAs can bind to luminal bacteria,
p
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reventing microbial translocation across the epithelial barrier
209]. The innate lymphoid cells reside in the lamina propria and
ontrol the stimulations of T helper cells to regulate activation of
daptive immunology and development through cytokine shape
210]. These lymphoid cells that produce IL-22 are essential
or preventing the spread of microbes to systemic sites [211].
utrients derived from the host diet are critically important in
haping the structure of host-associated microbial communities
212]. Epithelial cells also secrete antibacterial substances that
an shape the composition of intestinal microbial communities.
ome antimicrobial proteins, such as -defensins, can shape the
verall community composition. RegIII has restricted effects
n surface-associated bacteria and thus controls the location of
icrobes relative to host surface tissues.
Sensing of commensal microbiota through the TLR-MyD88
ignaling pathway triggers several responses critical for main-
aining host-microbial homeostasis. Homeostasis is maintained
y a system of checks and balances between pro- and anti-
nflammatory cytokines. Th1 cells produce interferon-, and
h17 cells produce IL-17, IL-17f, and IL-22. These cytokines
ct as effector features resembling Th2, Th17, and Treg cells.
olysaccharide A (PSA) of Bacteroides  fragilis  can induce an
L-10 response in intestinal T cells, which prevents potential
amage to the mucosal barrier [213]. A recent study revealed
hat the microbiota have a role in the control of the function
f invariant NK T cells (iNKTcells), which bear an invariant T
ell receptor specific for lipid antigens presented by the atypical
lass I molecule. Germ-free mice were found to have increased
usceptibility to iNKT cell-mediated oxazolone-induced colitis
nd ovalbumin-induced asthma. More interestingly, this effect
ould be reversed only if mice were exposed to the micro-
iota during the neonatal period. The regulation of iNKT cell
xpansion was ascribed to reduced expression of the chemokine
XCL16 in the presence of microbiota. Thus, signals elicited
y commensals may repress systemic expression by epithelial
ells of a chemokine that interacts with CCR6 and is selectively
xpressed by iNKT cells [214]. This may make us believe that
it’s okay to let your toddler lick the swing set and kiss the
og”.
There are a series of monogenic conditions of the nucleotide-
inding oligomerization domain (NOD) receptor family that are
onsidered to be autoinflammatory. Studies have shown that
LR ligands can trigger proinflammatory IL-1 secretion in
he presence of activated NLR family pyrin domain containing
 (NLRP3) mutations [215]. TLR4 and 9 signal transduction
ncreases TNF  expression. In humans, TNF  promotes insulin
esistance and the accumulation of fat in the liver. Together,
hese examples show that innate immune system defects can
esult in dysbiosis of the intestinal microbiota with downstream
etabolic consequences for the host.
There is a primary question as to whether probiotics exert
heir beneficial fuctions by themselves or through metabolic
roducts. Fukuda et al. [216] concluded that bifidobacteria can
rotect against enteropathogenic infection by the production of
cetate [217]. The human gut is colonized with a wide variety
f microorganisms, such as Bifidobacterium, that have benefi-
ial effects on human physiology and pathology [218]. Studies
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sing this model have shown that Stx (both Stx1 and Stx2) pro-
uced by Escherichia  coli  O157 is a crucial factor in lethal
nfection [219], and that pretreatment with certain probiotics,
ncluding bifidobacteria, can protect mice against death [220].
hen germ-free mice were fed with E.  coli  O157, they died
ithin 7 days. However, mice survived if they had been col-
nized Bifidobacterium  longum  subsp. Longum JCM 1217T
BL) 7 days before inoculation with E.  coli  O157. By contrast,
nother strain of bifidobacteria, Bifidobacterium  adolescentis
CM1275T (BA), failed to prevent E.  coli  O157-induced death
nder the same conditions. The researchers also found that serum
oncentrations of Stx2 were markedly lower in BL1O157 mice
han in BA1O157 mice, suggesting that BL, but not BA, pro-
otes epithelial defence functions that prevent the translocation
f Stx2 into the blood. SCFAs are the major end products of
arbohydrate metabolism by bifidobacteria. Indeed, the concen-
ration of acetate alone was found to be significantly higher in
he feces of mice with the preventive strain compared with those
ith the non-preventive strain. These results suggest a positive
orrelation between the amount of fecal acetate and the resis-
ance of mice to infection with E.  coli  O157. These data also
uggest that acetate produced in large amounts by the preven-
ive bifidobacteria exerts its action on the colonic epithelium by
nducing anti-inflammatory and/or anti-apoptotic effects, block-
ng the translocation of the lethal dose of Stx2 into the blood.
CFAs generated by commensal bacteria have long been impli-
ated in a variety of beneficial effects on the host, including
rophic and anti-inflammatory effects on the gut in  vivo  [214].
he latest findings strongly suggest that bacterial acetate acts
n vivo  to promote the defence functions of host epithelial cells.
. The  gut  is  not  only  a site  of  nutrient  transfer,  but  also
n important  information  exchange  system
The gut is the largest endocrine organ in the body. Gut
ormones can be classified into many families based on their
tructure, and each family originates from a single gene. A
ormone gene is often expressed in multiple peptides due to
andem genes, alternative splicing, or differentiated posttransla-
ional processing. By these mechanisms, more than 100 different
ormonally active peptides are produced in the GI tract. In addi-
ion, gut hormones are widely expressed outside the gut. The
ifferent cell types often express different products of the same
ene and release the peptides in different ways. Therefore, the
ame peptide may act as a hormone as well as a local growth fac-
or or neurotransmitter. This suggests that GI hormones should
e conceived of as intercellular messengers of major general
mpact. From the beginning, GI endocrinology has been central
o our understanding of multicellular life, health, and disease. In
ther words, the functions of the body are known to be regulated
ot only by nerves, but also by hormones. The regulation of pan-
reatic secretion (exocrine and endocrine) remains a major issue
n gut endocrinology [221].Recently, novel cell surface and soluble signaling molecules
roduced by cells of the immune system have been discovered
hat regulate host responses to microorganisms found mainly
n the gut. It is now widely appreciated that these molecules
n
t
o
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nteract in a concerted fashion to maintain a balance that
overns an appropriate response to infectious organisms. Sev-
ral classes of these compounds, including proteins, peptides,
ipopolysaccharides, glycoproteins, and lipid derivatives, have
een characterized as molecules that have potent effects on the
ost immune system. Peptides such as cytokines and chemokines
re well-known examples of such molecules. Whereas polysac-
harides have been believed to have beneficial functions, certain
hytochemicals have recently been shown to act as potent
mmunomodulating agents. However, the unavoidable ques-
ion is how polysaccharides exhibit biological activity under
on-digestion conditions. With recent advances in the under-
tanding of how cells communicate with each other to signal
ffector functions, it has become possible to conceive of strate-
ies to manipulate these signaling pathways and influence host
esponses. Compounds that are capable of interacting with the
mmune system to upregulate or downregulate specific aspects
f the host response can be classified as immunomodulators or
iologic response modifiers. These compounds are more likely
o be found in the gut than be absorbed into circulation and
each a target site. Recently, certain polysaccharides have been
escribed as potent immunomodulators with specific activity for
oth T cells and APCs.
.1.  The  information  exchange  system  of  the  gut/liver  axis
Enterohepatic circulation serves to capture bile acids and
ther steroid metabolites produced in the liver and secreted to the
ntestine for reabsorption back into circulation and reuptake by
he liver. This process is under tight regulation by nuclear recep-
or signaling. Bile acids produced from cholesterol can alter
ene expression in the liver and small intestine by activating the
uclear receptors farnesoid X receptor (FXR; NR1H4), pregnane
 receptor (PXR; NR1I2), vitamin D receptor (VDR; NR1I1),
 protein-coupled receptor TGR5, and other cell signaling path-
ays (JNK1/2, AKT and ERK1/2). Among these controls, FXR
s known to be a major bile acid-responsive ligand-activated
ranscription factor and a crucial control element for maintain-
ng bile acid homeostasis. FXR has a high affinity for several
ajor endogenous bile acids, notably deoxycholic acid, cholic
cid, lithocholic acid, and chenodeoxycholic acid. By respon-
ing to excess bile acids, FXR acts as a bridge between the liver
nd small intestine to control bile acid levels and regulate bile
cid synthesis and enterohepatic flow. FXR is highly expressed
n the liver and gut, and contributes to the maintenance of choles-
erol/bile acid homeostasis by regulating a variety of metabolic
nzymes and transporters. FXR activation also affects lipid and
lucose metabolism, and can influence drug metabolism [222].
Several structurally diverse compounds show high-affinity
inding and agonist activity toward FXR, including steroids,
romatics, terpenoids, alkaloids, and FAs. Many compounds
nrelated to bile acids can also act as FXR ligands, including
ndrosterone, guggulsterone, stigmasterol, and the exogenous
atural plant sterol forskolin [223]. In the intestine, FXR controls
he absorption of bile acids, lipids, vitamins, certain drugs, and
ther xenobiotics through the regulation of expression of four
mportant transporters, apical sodium-dependent transporter,
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A-binding protein subclass 6 (FABP6), which is also known
s intestinal bile acid-binding protein (I-BABP), and organic
olute transporters that are responsible for the transport of bile
cids from the intestine to the portal system. The major bile acid
ransport (ASBT) system in ileal enterocytes transports bile
cids into the ileal enterocyte brush border (apical) membrane
224]. In humans, the ASBT gene is activated by retinoic
cid, which has implications for the treatment of patients with
holestasis or chronic diseases of the GI system with vitamin A
nd retinoic acid-based drugs [225]. Intestinal FXR activation
lso affects hepatic events. FGF19 is highly expressed in the
mall intestine [226]. When secreted from the intestine, FGF19
irculates to the liver and suppresses bile acid through the bind-
ng and activation of the FGF receptor 4 (FGFR4)/-Klotho
omplex located on the surface of hepatocytes and other epithe-
ial cells [227]. Activation of the FGFR4/-Klotho complex
timulates the c-Jun N-terminal kinase (JNK) pathway, even-
ually suppressing the gene encoding CYP7A1, the cholesterol
-hydroxylase, and the rate-limiting bile acid synthetic enzyme
228].
In addition to being a major regulator of bile acid homeosta-
is, FXR plays an important role in the intestinal defense against
nflammation, interacting with nuclear factor-kappaB (NF-B)
ignaling. Exposure of LPS-activated macrophages to an FXR
igand leads to the reciprocal regulation of NF-B-dependent
enes such as TNF  and IL-1  [229]. Intestinal FXR activation,
esponding to bile acids, controls bacterial growth and main-
ains mucosal integrity, regulating the expression of a variety
f genes involved in defense against inflammation and mucosal
rotection. Therefore, FXR might be a critical factor regulat-
ng intestinal innate immunity and homeostasis. FXR is also
xpressed in pancreatic -cells and regulates insulin signaling.
embers of the CYP3A family of cytochrome P450 expressed
n the liver and intestine are also involved in bile acid metabolism
y catalyzing hydroxylation of bile acids at different positions
230]. Human hepatic CYP3A4, the dominant CYP3A in the
uman liver, metabolizes a number of xenobiotic compounds
ncluding many drugs in clinical use [231]. This enzyme is also
ighly expressed in the intestine where it plays an important
ole in first-pass metabolism of many orally administered drugs
232].
Once taken up, endogenous chemicals and toxic and xeno-
iotic compounds pass though the small intestine and liver, and
iffuse into the whole body via  the circulatory system. In these
wo sites, FXR plays an important role in protecting against
otential toxicity. Recent discoveries have suggested that alter-
tion of FXR signal transduction really plays important roles
etween the liver and gut. We believe that most phytochemicals
xert their benefic roles through interactions with these FXRs.
.2. The  information  exchange  system  of  the  gut/brain  axis
Peptide hormones released from the gastrointestinal tract
ommunicate information about the current state of energy bal-
nce to the brain. These hormones regulate appetite and energy
xpenditure via  the vagus nerve or by acting on key brain regions
mplicated in energy homeostasis such as the brainstem and
s
w
s
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ypothalamus. Sam et al. [233] published an overview of the
ain gut hormones implicated in the regulation of food intake.
eripheral signals from the gut and adipose tissue constitute
eedback mechanisms that enable maintenance of a steady body
eight despite daily variations in energy expenditure and nutri-
nt intake.
The role of peripheral hormones and the gut/brain axis in the
egulation of appetite has been of interest in recent years because
f the growing crisis of global obesity and metabolic disease.
besity has become a major public health problem worldwide
234]. Gut-brain cross-talk is involved in the regulation of food
ntake.
(1) Neuroendocrine control of appetite. The hypothalamus
nd the brainstem are the main central nervous system regions
esponsible for the regulation of energy homeostasis. These
rain areas receive peripheral neural and hormonal signals that
elay information about acute nutritional state and adiposity
235]. Neural afferents and hormonal signals from the periph-
ry are integrated with higher brain center signals to regulate
ppetite and energy expenditure [236]; (2) there are at least
5 different types of enteroendocrine cells diffusely distributed
hroughout the GI epithelium. These cells produce and release
 variety of hormones and signaling molecules, which together
onstitute the largest endocrine organ of the body [237]; (3)
ormone peptides, like neuropeptide Y (NPY) and pancreatic
olypeptide (PP), belongs to the ‘PPfold’ family of proteins.
hese peptides are 36 AAs in length and share a common tertiary
tructural motif known as the PP-fold. C-terminal amidation of
hese proteins is necessary for biological activity. PYY exists
ndogenously in two forms: PYY1-36 and PYY3-36 [238]. The
nzymatic cleavage of secreted PYY1-36 at the amino terminal
y the cell surface enzyme dipeptidyl peptidase IV (DPP-IV)
ives rise to PYY3-36, the predominant form of circulating PYY
mmunoreactivity [239]; (4) glucagon-like peptide-1 (GLP-1).
he 2 bioactive forms of GLP-1, GLP-17-37 and GLP-17-36
mide, are released into circulation from L cells of the GI tract
n response to an oral glucose load. Physiologically, GLP-1
s an important incretin, stimulating glucose-dependent insulin
elease. In addition to its incretin effect, GLP-1 also inhibits
he secretion of glucagon, thereby inhibiting endogenous glu-
ose production. The effect is to reduce blood glucose after a
eal. GLP-1 also delays gastric emptying, and increases satiety;
5) gut hormones regulating food intake. The GI tract releases
ore than 20 different regulatory peptide hormones that influ-
nce a number of physiological processes. Gut hormones act on
issues such as smooth muscle, exocrine glands, and the periph-
ral nervous system [240]. The release of gut hormones such as
YY, GLP-1, and oxyntomodulin (OXM) is stimulated by dis-
ension of the stomach and interactions between nutrients and
he luminal wall of the intestine; (6) oxyntomodulin (OXM).
XM is a 37 AA peptide that is released post-prandially from
 cells in proportion to caloric intake. OXM also delays gastric
mptying and reduces gastric acid secretion. In addition, it was
hown to reduce food intake in normal-weight human volunteers
hen administered intravenously. When administered to obese
ubjects, it reduced both food intake and body weight [241];
7) pancreatic polypeptide (PP). PP is released post-prandially
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nder vagal control by pancreatic islet PP cells [242]. PP is
ecreted in proportion to caloric intake. Circulating levels rise
fter meals and remain elevated for up to 6 h post-prandially;
8) glucagon. Glucagon is a 29 AA peptide secreted from the
-cells of the pancreatic islets of Langerhans. It is a further
roduct of pre-proglucagon cleavage alongside OXM and GLP-
. Glucagon is released into the portal vein in fasting states and
lso in response to exercise, and acts on the liver to promote
epatic glycogenolysis and gluconeogenesis to maintain gly-
aemic balance. Glucagon mediates its effects via  the glucagon
eceptor, GPCR. It is expressed in the gut, brain, and many other
rgans [243]; (9) cholecystokinin (CCK). CCK is released post-
randially from the small intestine, and has also been shown to
o-localise with PYY in L cells. Two types of CCK receptor
ave been identified in the CNS and peripheral tissues. CCK1
eceptors are present in peripheral tissues such as the pancreas,
allbladder, and on vagal afferent nerve fibers innervating the
ut [244]. CCK1 receptors within the CNS and dorsomedial
ypothalamus have been shown to be involved in the regulation
f food intake. The CCK2 receptor is found in the hypothalamus,
agal afferents, and gastric mucosa, and is known to be involved
n appetite regulation; (10) Ghrelin. Ghrelin is a 28 AA acylated
eptide secreted in the stomach. It was originally identified as
n endogenous ligand and a growth-hormone-releasing peptide
245].
More recently, Duraffourd et al. [246] showed that -opioid
eceptors (MORs) present in nerves in the portal vein walls
espond to peptides to regulate a gut-brain neural circuit that con-
rols intestinal gluconeogenesis and satiety. Peptides and protein
igests behaved as MOR antagonists in competition experiments
n vitro. These stimulate MOR-dependent induction of intesti-
al gluconeogenesis by activation of brain areas receiving inputs
rom GI ascending nerves in  vivo. MOR-knockout mice do not
arry out intestinal gluconeogenesis in response to peptides and
re insensitive to the satiety effect induced by protein-enriched
iets. Thus, the regulation of portal MORs by peptides triggering
ignals to and from the brain to induce intestinal gluconeo-
enesis are links in the satiety associated with dietary protein
ssimilation. MORs expressed in the mesenteric-portal area
ontrol a gut-brain neural circuit involved in the regulation of
ntestinal gluconeogenesis [247]. The regulatory role of MORs
n the control of food intake has been largely documented for
he central nervous system, and is related to their roles in the
o-called “reward” system [248]. Duraffourd et al. [246] also
emonstrated that MORs play a role in mediating the satiety
ffects of diet proteins, acting within a neural gut-brain circuit.
ral intake of various -opioid antagonists decrease hunger in
umans despite the fact that they do not reach the brain due to
xtensive first-pass hepatic metabolism [249].
Harrold et al. [250] also showed that key peripheral episodic
nd tonic signals from orexigenic or anorexigenic agents can
lso control the central nervous system. Research suggests that
uctuations in the availability or utilization of energy-yielding
ubstrates (mainly glucose and FAs) control eating behavior.
educed ATP levels due to a decrease in FA oxidation or glu-
ose utilization increases the AMP/ATP ratio and activates the
biquitous cellular energy sensor AMP kinase (AMPK), which
c
t
c
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xists in the periphery and in the brain. AMPK activation or deac-
ivation in the hypothalamus increases or decreases food intake
251]. Pathways in the CNS that are sensitive to this metabolic
ignaling have begun to be elucidated. However, direct entry of
etabolites and their action on receptors in the CNS may also
ontribute to their effects on satiety. Chemicals released by the
I tract during digestion also act as satiety signals in the control
f appetite.
.3.  Gut  cannabinoid  signaling  regulates  inflammation  and
nergy balance
The control of energy balance is one of the most highly inte-
rated and complex functions of the body. Disturbances in the
egulation of energy balance frequently lead to the develop-
ent of obesity. The major control systems of energy balance
ie in the brain. These centers integrate information from the
ody and initiate appropriate behavioral, humoral, and neural
utputs. The energy balance centers of the brain receive impor-
ant inputs from the GI tract, liver, pancreas, adipose tissue,
nd skeletal muscle, and are mediated by a series of different
ignaling molecules [252]. The role of the gut has been partic-
larly highlighted in the control of energy balance. Obesity is
ow characterized as a systemic low-grade inflammatory con-
ition with cells of the immune system directly involved in the
etabolic and homeostatic abnormalities that lead to many of
ts co-morbidities, including diabetes and liver disease [253].
 question that arises is whether there is a connection between
he microbiota of the GI tract, the development of an inflamma-
ory state, and the control of energy balance. Recent evidence
uggests that the endocannabinoid system may be a major medi-
tor. Endogenously produced lipid-mediators that act on the
annabinoid (CB)1 and CB2 receptors have been implicated in
he control of food intake and energy balance, the regulation of
nflammation, and in gut-adipose tissue signaling. Cluny et al.
252] reviewed and discussed how the endocannabinoid system,
ntestinal microbiota, and the brain-gut axis are involved in the
egulation of energy balance and the development of obesity-
ssociated systemic inflammation. The endocannabinoid system
lays a major role in the regulation of energy homeostasis and
s generally upregulated in obese states. It is also implicated in
he development of low-grade inflammation in obesity by con-
rolling intestinal permeability through actions mediated by the
mmune system. The fact that the microbiota influence signaling
n the endocannabinoid system to regulate inflammation and
dipose tissue metabolism suggests that dietary interventions to
lter gut bacteria may be a novel avenue to explore alternative
eans of activating the endocannabinoid system while avoiding
irect stimulation of global CB1 receptors.
.4.  CCR6  as  a  mediator  of  immunity  in  the  lungs  and  gut
Chemokines constitute a family of structurally related
hemotactic cytokines that direct the migration of leukocytes
hroughout the body under both physiological and inflammatory
onditions [254]. While most chemokine receptors bind to mul-
iple chemokines, the chemokine receptor CCR6 has only one
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hemokine ligand, CCL20 (macrophage inflammatory protein-
, MIP-3) [255]. CCL20 is expressed by a variety of epithelial
ell types including pulmonary epithelial cells and IECs [256].
CL20 is typically expressed at a low basal level, but can be
trongly induced by pro-inflammatory signals including primary
ytokines (e.g., TNF-) and TLR agonists. The production of
CL20 by human bronchial epithelial cells is regulated by the
ro-inflammatory cytokines TNF-  and IL-1, and also by pro-
llergic cytokines IL-4 and IL-13, which are known to influence
CL20 expression by activation of both the ERK1/2 and p38
APK pathways [257]. CCR6 is also expressed on immature
Cs, most B cells, subsets of CD4+ and CD8+ T cells, and
KT cells [258]. Studies have also shown that CCR6 is a spe-
ific marker for Th17 cells and Treg cells and distinguishes them
rom other T helper cells [259]. DCs are the most potent class
f APCs in the immune system that induce primary immune
esponses against invading pathogens, suggesting that DCs are a
ey leukocyte population involved in driving the innate immune
esponse. Immature DCs express various chemokine receptors
uch as CCR1, CCR2, CCR3, CCR5, CCR6, and CXCR4 [260].
nce immature DCs take up antigens in mucosal tissues, these
Cs gain a mature status by down-regulating CCR6 expres-
ion [261]. They then home to regional lymph nodes through
fferent lymphatic vessels via  the interaction of CCR7 with its
igands. Upon arrival in the regional lymph nodes, the mature
Cs become effective APCs.
The CCR6/CCL20 axis plays an important role in intestinal
mmunity. During normal development and immune homeosta-
is, CCR6-mediated signals help to organize lymphoid tissues
uch as Peyer’s patches, mesenteric lymph nodes (MLNs), and
ALT by recruiting lymphoid and myeloid cells, including
Cs and macrophages. In addition, CCR6-mediated signals are
entral to innate immune responses to normal intestinal flora.
he relative CCR6-dependent chemotactic response of DCs
nd macrophages, and the subsequent activation and effector
unction of these cell populations, may also play an impor-
ant role in intestinal immune responses [262]. In the gut, areas
f PPs, isolated lymphoid follicles (ILFs), MLNs, and GALTs
how constitutive expression of CCL20, which is important
or the chemotaxis of immature DCs [263]. CCR6/CCL20-
ediated signals can induce chemotaxis of CCR6-expressing
Cs and macrophages to sites of infection to help in the immune
esponse. These findings suggest that CCR6-mediated signals
n macrophages and DCs may be important for cell activation
uring exposure to microbes and microbial products in gut.
Conventional and plasmocytoid DC subsets are found in
any lung compartments including the airway epithelium, lung
arenchyma, visceral pleura, and the bronchoalveolar space,
hich attests their importance in the maintenance of respira-
ory health [264]. Immature DCs are highly abundant in human
ung parenchyma where they express low levels of the costimula-
ory molecules CD80 and CD86, actively display antigen uptake
roperties, and constitutively express the chemokine receptors
CR1 and CCR5. DCs are constantly recruited into the lungs,
here they recognize inhaled antigens that transform them into
PCs and migrate to the draining pulmonary lymph nodes where
hey activate antigen-specific CD4+ and CD8+ T cells. Many
a
a
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ells in the lung produce a wide array of chemokines that orches-
rate the recruitment of DCs into the lungs based on the original
timulus. Various cytokines have been shown to regulate CCR6
xpression in lung DCs. Studies have shown that epithelial
irway cells exposed to the inflammatory cytokines IL-1,
NF-, and IFN-  produce IL-15, which cause monocytes to
ifferentiate into partially mature DCs that have characteristics
f plasmocytoid DCs [265]. These data suggest that a pathogenic
h2 response is decided by CCR6/CCL20-dependent recruit-
ent of conventional DCs to the lungs [266].
.5. Ghrelin’s  actions  on  the  reproductive  axis
Ghrelin is a peptide hormone secreted from the stomach into
irculation, but it can also be synthesized in several other tis-
ues and exert both endocrine and paracrine effects. To date, its
xpression and activity have been documented in various repro-
uctive tissues, indicating that ghrelin regulates several aspects
f reproductive physiology and pathology [267]. The evidence
ndicates that ghrelin participates in the regulation of reproduc-
ive physiology by 2 distinct and probably overlapping actions:
i) through systemic release of the stomach-derived peptides,
hich act at different levels of the reproductive system, and (ii)
hrough biological effects on reproductive organs induced by
ocally expressed ghrelin [268]. Besides of its acute effects on the
eproductive axis, ghrelin may have a more chronic or long-term
ction on various aspects of reproduction, such as puberty, which
s highly sensitive to energy stores. Ghrelin’s central effects on
he reproductive system also involve modulation of prolactin
ecretion.
It has been suggested that rat gonadal ghrelin expression is
 function of the estrous cycle as its present at increased con-
entrations in the cytoplasm of luteal-phase steroidogenic luteal
ells [269]. A number of growth factors and cytokines released
rom the reproductive tract and the preimplantation embryo exert
 paracrine and autocrine influence on the rate of embryo devel-
pment, the proportion of embryos developing to the blastocyst
tage, the cell number in the blastocyst, and the rate of apopto-
is [270]. Ghrelin may also be involved in these processes as
 chemical messenger mediating intercellular communication.
esearch has revealed strong ghrelin expression in the human
lacenta during the first trimester, especially in extravillous tro-
hoblasts (EVT) on the tips of the chorionic villi [271]. Since
aternal ghrelin crosses the feto-placental barrier [272], it could
e critical for fetal development. A pattern of testicular expres-
ion of ghrelin and its cognate receptor has been demonstrated
n humans [273]. Ghrelin’s actions may have implications not
nly for the control of spermatogenesis, but also for Leydig cell
roliferation, with an inhibitory role in reproductive function-
ng during states of malnutrition. Since the reproductive axis is
ighly dependent on body energy status, ghrelin could be a signal
inking nutritional status to the hypothalamus–pituitary–gonad
xis (HPGA).Proper maturation and function of the reproductive axis
re essential for perpetuation of the species, and so they
re subjected to the fine regulation of different central and
eripheral signals affecting the so-called HPGA [274].
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eproductive function is highly energy demanding, but not
rucial for the survival of the individual. During evolution,
ophisticated mechanisms have been selected to allow the
hutting down of the HPGA in conditions of energy insuffi-
iency. Several neuroendocrine integrators jointly participate
n the physiological–pathophysiological control of energy
alance and reproductive development [275]. Mucciolia et al.
274] summarized ghrelin’s actions on the reproductive axis
s follows: (1) effects on gonadotropin secretion. A complex
ode of action of circulating ghrelin on the HPGA has
een documented that includes inhibition of hypothalamic
onadotropin-releasing hormone (GnRH) release; (2) effects
n puberty. Ghrelin delays pubertal onset in both males and
emales, but males appear to be more sensitive than females; (3)
ffects on prolactin. Ghrelin’s central effects on the reproductive
ystem also involve modulation of the secretion of prolactin,
 pituitary hormone that inhibits gonadotropin secretion; and
4) intratesticular ghrelin administration has also been shown
o inhibit the proliferative rate of immature Leydig cells during
uberty and after selective ablation of mature Leydig cells by
thylene dimethane sulfonate treatment in  vivo.
Given the above findings, it appears there are a series
f signaling pathway networks between the gut/brain,
ut/endocrine system, gut/liver, gut/lungs, gut/cardiovascular
ystem, and even the gut/reproductive system. This raises the
uestion of how for the GI tract communicates with these organs
nd systems. We strangly suggest that it is simply a cyclic sys-
em.
. Some  functional  foods  cannot  be  absorbed,  but  have
reat  effect  on  cytokines  and  chemokines
The intestinal mucosa is constantly exposed to the luminal
ontents, which include microorganisms and dietary com-
onents. Probiotic non-digestible oligosaccharides may be
upplemented to modulation immune responses in the intes-
ine. Intestinal epithelial cells lining the mucosa are known to
xpress carbohydrate (glycan)-binding receptors that may be
nvolved in the modulation of mucosal immune responses. The
I immune system is the largest and most complex immunolog-
cal tissue in the human body, and it can constantly discriminate
etween harmless and dangerous compounds. IECs express sev-
ral receptors that recognize antigens and semiantigens present
n the intestinal lumen as well as the receptors described above.
hese receptors could be the most important information deliv-
ry systems and could play critical roles in the bioactive effects
f functional foods or oral vaccines and/or medicines.
.1. Polysaccharides
Numerous dietary polysaccharides, particularly glucans,
ppear to elicit diverse immunomodulatory effects in numerous
nimal tissues, including the blood and GI tract [276]. Glycan-
inding receptors, which are also called lectins, include the
amily of the C-type lectin receptors, galectins, and siglecs [277],
hich recognize different glycan structures. APCs and IECs
re important sensors and regulators of potential danger signals
t
o
b
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ithin the intestine and are crucial in the cross-talk between
uminal antigens and immune cells. Dietary supplementation
ith non-digestible oligosaccharides has been shown to reduce
he risk of developing allergic diseases and to suppress acute
llergy symptoms such as acute allergic skin responses in ani-
al and clinical studies [278]. Dietary supplementation with a
pecific probiotic mixture of short-chain galacto-oligosa-
charides (scGOS) and long-chain fructo-oligosaccharides
lcFOS) in a 9:1 ratio was shown to suppress the development
f acute allergy symptoms, possibly involving the induction of
reg cells [279].
.1.1.  Glycan  recognition
Different subsets of intestinal DCs have been described that
an induce Th1, Th2, Th1, or Treg cell effector responses upon
ctivation [280]. In order to induce an immune response or oral
olerance, antigens must be recognized, and DCs as well as IECs
xpress receptors that recognize glycan structures. These sensors
nclude: (1) C-type lectins. Expression of membrane-bound C-
ype lectins is mainly restricted to APCs, including DCs and
acrophages [281]. C-type lectins are classified into groups
f proteins that contain one or more carbohydrate recognition
omain (CRD) and proteins that contain a C-type lectin-like
omain without a CRD. DCs express a wide variety of receptors,
ncluding TLRs. C-type lectins recognize specific carbohy-
rate antigens and are mainly associated with antigen uptake
nd processing [282]. Several studies have shown that gly-
an recognition may be essential as activation of a specific
-type lectin, DC-specific intercellular adhesion molecule-3-
rabbing non-integrin (DC-SIGN), on DCs integrates TLR
ignaling, resulting in an IL-10-mediated immune response and
nduction of Treg cells [283]; (2) siglecs: sialic acid-binding
mmunoglobulin-like lectins are type I trans-membrane pro-
eins. Like the membrane-bound C-type lectins, siglecs are
xpressed on DCs and macrophages as well as almost all immune
ell types. Siglecs recognize sialylated glycans of which N-
cetylneuraminic acid is the most common; and (3) galectins:
lthough APCs can respond to carbohydrate structures directly,
ntigens first encounter a monolayer of epithelial cells. Like
PCs, IECs also express various TLRs and it has been shown
hat the expression of TLRs at the apical surface is increased
nder inflammatory conditions [284]. IECS also express vari-
us galectins. After secretion, galectins bind to glycoproteins or
eceptors at cell surfaces and so regulate cell functions. Galectins
re secreted by IECs as well as various immune cells, including
Cs, macrophages, and granulocytes [285]. Glycans can thus be
ecognized by different families of receptors that are expressed
n APCs and IECs. Non-digestible oligosaccharides are known
o be involved in maturation of the immune response of young
nfants, cytokine secretion, and oral tolerance induction, and
hey can reduce the risk of developing allergic diseases [286].
hese oligosaccharides are known to function as probiotics,
timulating the growth of lactic acid bacteria and Bifidobac-
eria in the colon of a host [287]. Although the beneficial effects
f probiotic oligosaccharides are known, the exact mechanisms
y which these occur are unclear. Human milk oligosaccharides
ave been shown to bind glycan-binding receptors including
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Table 1
Immune modulation by galectins.
Glycan-binding
receptor
Receptor/ligand Signal transduction Biological effect
Galectin-1 Glycoproteins on
CD4+CD25+ Treg
CD45 clustering on effector T cell
via cell-contact with Treg
Treg function ↑
Pro-inflammatory cytokines ↓; IL-10 secretion ↑; Treg
expansion
? iNOS activity ↓ NO production m	 ↓
? l-arginase activity ↑ Alternative activation m	; Pro-inflammatory cytokines ↓
TCR Partial 
-chain phosphorylation IL-2 ↓; IFN-, CD69 expression unaltered
CD2 (LFA-2) Modulation of APC-T cell
interactions
ECM proteins Cell adhesion/migration
Galectin-3 CD98 PI3 kinase ↑ Alternative activation m	 ↑
? Chemotactic for monocytes, neutrophils and mast cells
TCR TCR signaling ↓ T cell inactivation
NF-B ↑; AP-1 ↑ IL-8 ↑ by lamina propria fibroblasts
Galectin-4 Lipid raft stabilizer on intestinal epithelial cells
CD3 ? IL-10 ↑; TNF-, IL-17 ↓
? PKC ↑ IL-6 secretion CD4+ T cell ↑
Galectin-9 ? p38 ↑, ERK1/2 ↑ Increased dendritic cell maturation;
CD40/CD54/CD80/CD83/CD86/; HLA-DR ↑ IL-12 ↑, Th1
cytokines ↑
TIM-3 Th1/Th17 cell apoptosis, Treg induction
IgE Suppression of mast cell degranulation
CD44 Prevention CD44-hyaluronic acid interaction; inflammation ↓
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-type lectin receptors and galectins [288]. The recognition of
lycans by C-type lectins or galectins may regulate immune
esponses [289]. Although TLRs and glycan-binding receptors
re widely expressed by different cell types in the intestine,
he communication and interactions between these cells are just
eginning to be understood. The known glycan-binding recep-
ors, ligands, signal transductions, and biological effects are
ummarized in Table 1.
.1.2.  Cytokine  secretions  induced  by  polysaccharides
In recent years, many studies have focused on the immunoreg-
lation of polysaccharides, which have mainly been isolated
rom plants or probiotics. A number of different effects on
mmunoregulation and cytokine secretion have been elucidated
n multiple studies. Table 2 displays data published since 2011.
Polysaccharides, especially the non- and poorly digestible
olysaccharides, have been shown to beneficially affect one
r more targeted cellular functions in  vitro, but a few in  vivo
tudies have also been published. Scientists are interested in the
mmunologic effects of dietary intake, but it is unclear whether
olysaccharides that elicit effects in  vitro  or by injection are
neffective or have different effects when taken orally [315].
ne can only speculate on the mechanisms involved, particu-
arly when one considers the exceedingly complex environment
f the GI tract. It is possible that fragments of polysaccharides
artially hydrolyzed by gut bacteria may either bind to the gut
pithelia and exert localized and/or systemic immune effects or
e absorbed into the bloodstream (but even here these may be
o
e
ainflammatory cytokines ↓
ic oxide; TCR, T cell receptor; Treg, regulatory T cell [406]. ?, uncertain.
apidly catabolized!) where they can potentially exert systemic
ffects. Further studies are needed to determine the optimal
iming and duration of polysaccharide ingestion. That is, should
olysaccharides be consumed continuously, before, at the time
f, or after exposure to a pathogen or environmental insult?
nly a few studies have actually investigated the impact of the
iming of polysaccharide intake on the achievement of optimal
enefits. Daily feeding of certain polysaccharides appears to
esult in tolerance (and diminished benefits) in some mushroom
-glucans [316].
Most studies have suggested that certain polysaccharides
ffect immune system functions. However many are in  vitro
tudies or studies of the injection of polysaccharides and, as
entioned earlier, their immunologic effects following oral
dministration are less clear. Functional foods are ingested and
ot injected. So it is really incredible for the results by adding
pecimens to the cultured cell lines, the reason just because of
he complex cell communications in  vivo, nether in the cultured
ell lines! Ramberg et al. [317] published a review evaluating
he available data regarding the specific immunologic effects
f dietary polysaccharides. They found 62 publications repor-
ing statistically significant effects of orally ingested glucans,
ectins, heteroglycans, glucomannans, fucoidans, galactoman-
ans, arabinogalactans, and mixed polysaccharide products
n rodents. Only 15 controlled human studies reported that
ral glucans, arabinogalactans, heteroglycans, and fucoidans
xerted significant effects. Although some studies investigated
nti-inflammatory effects, most investigated the ability of oral
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Table 2
The cytokine secretions and immunoregulations induced by polysaccharides (since 2011–present).
Polysaccharide Source (species) Results Study/design routes Reference
Polysaccharides (MP) Strawberry and
mulberry fruit
IL-1 and IL-6 ↓ IL-10 ↑ Lipopolysaccharide
(LPS)-stimulated mouse primary
macrophages
[290]
An exopolysaccharide (EPS) Bifidobacterium Slight stimulation of proliferation of
peripheral blood mononuclear cells; IL-1,
IL-17, and IL-8 ↑ (but no statistical
differences were detected)
Caco2 and HT29 cell lines;
peripheral blood mononuclear
cells (PBMCs)
[291]
Polysaccharide–protein
complex fraction 4
(LBPF4)
Lycium barbarum L. IL-6, IL-8, IL-10, TNF-, and IL-1 ↑ Mouse spleen cells, T cells, B
cells, and macrophages in vitro
and in vivo. Mice were injected
with LBPF4 everyday for 6 days
[292]
A polysaccharide (DOP) Dendrobium officinale Promoted splenocyte proliferation, enhanced
natural killer (NK) cell-mediated
cytotoxicity, and increased phagocytosis and
nitric oxide production by macrophages.
IL-2, IL-4 ↑
Evaluated the
immunomodulatory activity of
DOP with cell models in vitro
[293]
Water-soluble sulfated
polysaccharides
Enteromorpha
prolifera
Significantly increased ConA-induced
splenocyte proliferation; IFN- and IL-2 ↑
Determined immunomodulatory
activities in vitro and in vivo
[294]
Oligosaccharides and active
hexose correlated
compound (AHCC)
An edible
basidiomycete fungus
IL-1, IL-17, IFN- ↑ Human monocytes. CD4+ T cells [295]
Polysaccharide–protein
complexes
Longan pulp Splenocyte proliferation, macrophage
phagocytosis, and NK cell cytotoxicity ↑
Splenocytes, NK cells,
macrophages, and YAC-1
lymphoma cells in vitro
[296]
A water-soluble
polysaccharide (GP-I)
Gynostemma
pentaphyllum
TNF- ↓ anti-proliferative effects on HaCat
cells, and apoptosis ↑
HaCat cells [297]
A chitooligosaccharide
(COS)
11 genes including CCL20 and IL-8 ↑; 10
genes including CCL15, CCL25, IL-1,
TNF-, and NF-B ↓
Caco-2 cells [298]
A polysaccharide (LPPS) Lotus plumule TNF-, IL-6, ratio of IL-6/IL-10 ↓ in
splenocyte cultures; TNF-/IL-10 and
IL-6/IL-10 ↓ in the livers of NOD mice
Administered to non-obese
diabetic (NOD) mice to evaluate
the protective effects of LPPS on
type 1 diabetes
[299]
A protein-bound
polysaccharide (GSP-4)
Ganoderma sinense TNF-, IL-1, IL-12, and GM-CSF ↑ Human PBMCs and the RAW
264.7 murine
monocyte/macrophage cell line
[300]
Polysaccharides (GLPs) Ganoderma lucidum Maturation of DCs ↑, phagocytosis of DCs ↓
IL-12 ↑
Effects on dendritic cell (DC) cell
phenotypic maturation
[301]
A sulfated
heteropolysaccharide
Ophiopogon
japonicus
Macrophage activation by the promotion of
phagocytic capacity, energy metabolism,
NO, and IL-1 ↑
In  vitro [302]
North American ginseng (GS) IFN-, IL-23 and IL-6 ↑ TGF-, IL-13, and
LPS co-receptor CD14 ↓ MAPK (ERK-1/2),
PI3K, p38 and NF-kB cascades
In vitro [303]
A polysaccharide (PCP) Periostracum Cicadae NO, IL-1, IL-6, and TNF- ↑ induced
phosphorylation of ERK, JNK, p38, NF-B,
p50/p65
RAW 264.7 cells [304]
A polysaccharide (ABP) Achyranthes bidentata CD86, CD40, MHC II. ABP, IL-12 ↑ Induced phenotypic maturation
of DCs
[305]
A polysaccharide (AC) Antrodia camphorata IL-6, TNF-, IL-10, MCP-1 ↑ lung NF-B
expression ↓
Mice in vivo [306]
An ascophyllan Ascophyllum nodosum Transcription factors p65, degradation of
IB- ↑
RAW264.7 mouse macrophage
cell line
[307]
Polysaccharides Solanum nigrum L. IL-2, IL-10 and IFN- ↑ antitumour activity
↑
H22-bearing mice [308]
A polysaccharide (DP) Dendrobium officinale DP suppressed progressive lymphocyte
infiltration and apoptosis, and restored
balance to pro-inflammatory cytokine flux
An experimental SS mouse model [309]
A polysaccharide (RAP-W1) Rhizoma arisaematis INF- and IL-2 ↑ IL-10 ↓ BALB/c mice bearing human
breast cancer MCF-7
[310]
Fucoidin IL-8, TNF-, and iNOS expression by some Targeted against accelerated [311]
cytokines/chemokines ↓ cerebral ischemic injury in LPS
pretreated rats
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Table 2 (Continued)
Polysaccharide Source (species) Results Study/design routes Reference
Cryptoporus polysaccharide
(CP)
Cryptoporus TLR2 and NF-B mRNA levels of lung
tissues were decreased in CP-treated mice in
response to LPS
LPS-induced acute lung injury in
rats and mice
[312]
A polysaccharide (PPS) Polyporus umbellatus TNF-, IL-1 and NO of peritoneal
macrophages ↑ Blocking antibodies to
TLR-4, suppressed PPS-mediated TNF-
and IL-1 production
Immune responses of
macrophages
[313]
A polysaccharide (APS) Astragalus Shifting of Th2 to Th1 with enhancement of
T lymphocyte immune function, IL-10 ↓
Effect on the differentiation of
splenic DCs and on T
[314]
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polysaccharides to stimulate the immune system. Taken as a
hole, the literature on oral polysaccharides is highly het-
rogeneous and is insufficient for broad structure/function
eneralizations. Numerous dietary polysaccharides, particu-
arly glucans, appear to elicit diverse immunomodulatory
ffects in numerous animal tissues, including the blood, GI
ract, and spleen, but the mechanisms of these effects remain
nclear.
.2. Peptides  and  their  receptors  and  functions
Bioactive peptides derived from food and other sources have
een a focus of functional food research. Their activity in
itro and in  vivo  has mostly revealed antioxidant and anti-
yper/hypotensive effects. In order to exert such bioactivity, food
eptides must be either ingested and then reach the intestine in
heir intact form, or be liberated in  situ, that is, in the intestine,
rom their parent proteins to act locally, that is in the gut. Ingested
ood peptides rarely make it into the gut and across the mucosal
arrier. The proteins are degraded to very short peptides or are
ompletely hydrolyzed to AAs and few proteins are transported
ntact across the gut mucosal barrier [318]. Even those that do are
apidly hydrolyzed by enzymes or eliminated by innate immuno-
ogical cells such as macrophages. As a result, they rarely reach
heir targets. A promising delivery route for specific bioactivity
hrough food proteins is in  situ  peptide release (by host or gut
icrobial enzymes) with local activity in the gut; the effects of
uch proteins appear to be a result of interactions with numerous
eceptors. Bioactive peptides are usually either released through
rocesses such as fermentation or enzymatic hydrolysis to enrich
 fraction or extract for specific bioactive peptides or their pre-
ursors [319] or proteins are left intact in the final product and
he peptide bioactives are liberated in  situ  by the host digestive
ystem or gut microbial enzymes [320].
Identification and characterization of bioactive peptides has
een of increasing interest over the past decade. More than 150
cientific papers including “bioactive peptide(s)” in their title or
bstract are published a year whereas roughly 50 were published
nly ten years ago [321]. Bioactive peptides are of most interest
o researchers who are studying cancer, cardiovascular diseases,
iabetes, apoptosis, and angiogenesis. Although many peptides
erived from food proteins have been detected in the stomach
r small intestine, and even the cardiovascular system [322], the
resence of these peptides alone is not sufficient to establish
w
F
ocell-mediated immunity in vitro
heir bioavailability. The biggest threat to any bioactive peptide
s: (i) the lumen of the small intestine, which contains large
uantities of proteinase and peptidases, and (ii) the brush border
f the epithelial cells, which contains a series of peptidases [323].
ioactive peptides can only survive when their sequence resists
egradation. An alternative strategy is to reach the site of action
uickly after digestive release in  situ  and thus target receptors
ocated in the gut.
However, bioactive peptides generated from food proteins
nd even intact proteins can be absorbed in the intestine and
nduce biological functions at the gut or tissue level. For exam-
le, many reports have described a role for food-derived peptides
n increasing gut secretory and absorptive capacity or gut tis-
ue growth. In relation to milk, this has particular importance
n delivering bioactive proteins and peptides to infants with an
mmature GI tract mucosal barrier. Human milk contains not
nly antibodies and immune cells, but also many other sub-
tances that can interfere with bacterial colonization and prevent
ntigen penetration [324]. The gut has a complex receptor sys-
em that can transduct multiple signals and actually constitutes
 signaling pathway. Functional foods, medicines, and even
utrients can be censored and stringently controlled by the gut
hrough these receptors and ensure both homeostasis and health.
Many bioactive peptides are produced through preprandial
ermentation by bacteria, and the extent to which these are pro-
uced in  vivo  by luminal bacteria has yet to be directly studied
325]. Their effects on the host intestine include mucin produc-
ion and reduced blood pressure. Many of the effects of bioactive
eptides are receptor mediated and some such receptors have
een identified. However, many remain unknown. Interestingly,
ome attempts to isolate the bioactive fermentation products of
actobacillus helviticus  have lead to confusing results, as all
 peptide fractions collected had the same bioactive effects in
he host [326]. There are several examples of bioactive peptides
roduced by fermentation. -Casomorphin 7, a product of milk
ermentation, caused a dramatic increase in mucin production in
at intestinal explants [327]. This bioactive peptide acts directly
n the intestinal epithelium after absorption through -opioid
eceptors present on the basolateral side of goblet cells [328].
bservations have been made in  vivo, with goblet cell hypertro-
hy and hyperplasia of Paneth and goblet cells being induced
ith the administration of yoghurt fermented with L.  casei  [329].
ermentation products of L.  rhamnosus  also suppress the release
f prostaglandins through an opioid receptor-mediated response
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n IECs [330]. L.  johnsonnii  appears to produce a metabolite
hat lowers blood pressure via  a histaminergic receptor present
n the intestinal epithelium [331].
Bioactive peptide production is not limited to milk products.
ermentation of fish proteins also leads to potentially bioactive
eptides [332]. Consumption of bioactive peptides produced
rom the fermentation of milk and fish leads to an increased
umber of IgA (+) B cells in the lamina propria [333]. Fer-
ented fish protein also leads to increased production of pro-
nd anti-inflammatory cytokines IL-4, IL-6, IL-10, IFN, and
NF.
Soybeans, an excellent source of dietary peptides, have
eneficial effects on health. Dilshat-Yimit et al. [334] inves-
igated the effect of soybean peptide on immunoregulation,
rain function, and neurochemistry in healthy volunteers. They
ound that cell numbers were upregulated in the group who
ad fewer leukocytes but downregulated in the group with
ore leukocytes. For the lymphocyte-rich type, lymphocyte
ounts tended to decrease, accompanied by an increase in
ranulocyte numbers. For the granulocyte-rich type, granulo-
yte counts tended to increase, but lymphocyte counts also
ncreased.
.3. Phytochemicals
Phytochemicals have been shown to exert multiple bioac-
ive functions including antioxidant scavenging of ROS and
odulation of protein function. They dynamically regulate
he metabolic functions of proteins, enzymes, transporters,
eceptors, and signaling transduction proteins related to var-
ous lifestyle-related diseases [340–342]. These compounds
orm a very varied group: around 8000 species of phenolics
ncluding flavonoids, anthraquinones, and phenylpropanoids;
bout 25,000 terpenoids including terpenes, carotenoids,
anthophylls, and iridoids; 12,000 alkaloids; and several sulfate-
ontaining chemicals such as isothiocyanates. To date, numerous
tudies of phytochemicals have been published. Furthermore,
ew compounds beneficial to human health are constantly being
iscovered [335]. It is rather interesting that most phytochemi-
als are similar to Chinese herbal medicines [336]. This indicates
hat the mechanism of action of phytochemicals is similar to that
f traditional Chinese herbal medicines and healthy plant foods
337–339].
Only a very small amount of phytochemicals can be incorpo-
ated into the blood circulation, and levels of these chemicals in
lood are usually <1 M [343]. Phytochemical levels in blood
re independent of ingested amounts since they are regulated by
onjugation enzymes such as UDP-glucuronosyl transferases
nd phenol sulfotransferases below their Km values, which are
he concentrations of chemicals that the enzymes express affin-
ty for on the substrates. Therefore, the phytochemicals in blood
re mostly found in an inactive form. Most can interact with
ECs and transfer immune signals without uptake. Indeed, Moon
t al. [344] found that about two-thirds of quercetin was conju-
ated in IECs and showed antioxidant potency and prevented
everal cancers, atherosclerosis, cardiovascular diseases, and
steoporosis [345]. Thus, phytochemicals can have beneficial
d
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ffects on health, but most of these compounds undergo conju-
ation during the intestinal absorption process and are excreted
nto feces without being absorbed. Various compounds have
een found to be chemopreventive of degenerative diseases
ncluding flavonoids, prenyl chemicals, terpenoids, alkaloids,
ulfate-containing chemicals, and epigallocatechin gallate, all
f which are effective at very low concentrations. Isoflavone
an be converted to active equol by intestinal microorganisms
346]. Most phytochemicals exert their effects by interacting
ith GI systems. Furthermore, phytochemicals play roles simi-
ar to other functional compounds, such as polysaccharides and
ioactive peptides, which indicates that all of these function via
 similar mechanism, namely by interacting with GI systems,
specially the receptors throughout the GI, rather than by being
bsorbed into circulation [348,349].
17-Estradiol (E2), the most active estrogen, has profound
ffects on the growth, differentiation, and functioning of many
eproductive and non-reproductive tissues including the liver,
ardiovascular system, and brain. Most of E2 actions are exerted
ia two estrogen receptor subtypes (ER and ER), which are
embers of the nuclear receptor superfamily and regulate both
nique and overlapping physiological effects of E2. Most phy-
ochemicals are xenoestrogens. While these compounds mainly
xert their roles via  nuclear receptors, Marino et al. reviewed the
apid responses of estrogen receptors to xenoestrogens [350].
lavonoids are potentially able to protect against the devel-
pment of E2-dependent pathologies (e.g., endocrine tumors)
y binding to ER  and ER  [351]. Flavonoids show a higher
ffinity toward ER  than ER, but they are able to activate
oth receptors [352]. Xenoestrogens activate gene transcription
f both ER- and ER-dependent estrogen response elements
ERE), although different compounds show different degrees
f specificity toward ER  or ER  in terms of promoter acti-
ation. In addition to direct interaction with EREs, ERs can
egulate gene transcription without directly binding to DNA. In
his indirect genomic mechanism, ERs associate with specific
ranscription factors, such as Sp1, AP-1, and NFB, which in
urn mediates the binding of the complex to DNA. This mech-
nism can also be affected by xenoestrogens that impair the
R interaction with the transcriptional factors Sp1 and AP-
 [353]. In addition to transcriptional actions, ER  and ER
ediate E2-induced rapid effects, which occur within seconds
f E2 binding to the receptors. At this level, ligand-activated ERs
an interact with several other proteins involved in many differ-
nt signal transduction cascades, and thus form multi-molecular
omplexes that mediate the rapid signal transduction events
354]. However, to date, the ER-mediated extracellular regu-
ated kinase/mitogen activated protein kinase (ERK/MAPK) and
hosphatidyl-inositol-3-kinase/AKT (PI3K/AKT) pathways as
ell as the ER-mediated p38/MAPK signaling appear to be
he unique molecular circuitries activated by E2 in different cell
ontexts [355]. The bulk of the data that demonstrate the involve-
ent of the ER-based extra-nuclear effects in the regulation ofifferent physiological processes have been obtained mainly, if
ot exclusively, from in  vitro  model systems. Thus, the lack of
n in  vivo  model raises questions about the physiological rel-
vance of these E2-triggered effects. Nevertheless, recent data
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ave demonstrated that rapid extra-nuclear ER signaling occurs
n vivo  and also affects the regulation of specific physiological
rocesses in animal models [356]. Plant-derived polyphenols
ave diverse estrogenic biological activities due to their ability
o act as either estrogen agonists or antagonists depending on
he ER subtype present. These abilities have attracted a lot of
ttention as these compounds are potentially safe, effective
ietary estrogen replacements.
A well known phytochemical is resveratrol. Resveratrol [357]
s a polyphenol found in the skin and seed of grapes, and it can
xtend the life span of budding yeast [358]. Resveratrol has also
een linked to many physiological benefits, including protection
gainst cardiovascular disease, age-related deterioration, and the
athological consequences of fat-rich diets [359]. Resveratrol is
eported to exert its effects by directly activating the yeast Sir2
rotein and its mammalian homolog Sirt1. These members of
he Sirtuin family catalyze NAD+-dependent deacetylation reac-
ions. The Sirtuins have been independently linked to lifespan
egulation in budding yeast. However, the observed activation of
irt1 by resveratrol in  vitro  now appears to be an artifact of the
ssay used, casting doubt on the direct resveratrol-Sirt1 connec-
ion [360]. A series of studies showed that resveratrol activates
irt1 indirectly through AMPK, another energy-sensing enzyme
hat is required for many of the adaptations triggered by calorie
estriction [361]. AMPK promotes the activation of peroxi-
ome proliferator-activated receptor-coactivator 1  (PGC-1)
y Sirt1 through several mechanisms, including deacetylation
y Sirt1 and an increase in NAD+ concentration, which is rate
imiting for Sirt1 activity [362]. AMPK activation is the most
pstream signal triggered by resveratrol, but Sirt1 and AMPK do
ot appear to be a direct resveratrol target. More recently, Park
t al. [363] found that resveratrol inhibits phosphodiesterases
PDEs), leading to increased cAMP levels, Epac1 activation,
levated intracellular calcium, and AMPK activation. Calorie
estriction also activates AMPK. The increase of NAD+ levels
eads to Sirt1 activation, which promotes beneficial metabolic
hanges primarily through deacetylation and activation of PGC-
. In a parallel pathway, increased cAMP levels can also
ctivate PKA, which directly phosphorylates and activates Sirt1.
irt1 activation by either pathway, as well as the potential activa-
ion of other NAD+-dependent enzymes, can lead to numerous
hysiologic outputs. The metabolic effects of resveratrol result
rom competitive inhibition of cAMP-degrading phosphodi-
sterases, leading to elevated cAMP levels. As a consequence,
esveratrol increases NAD+ and Sirt1 activity. The metabolic
enefits of resveratrol mainly include prevention of diet-induced
besity and an increase in mitochondrial function, physical
tamina, and glucose tolerance.
. Which  is  the  agent  responsible  for  the  biological
unction, the  molecule  or  the  cell?
The cell is the fundamental unit of structure, function, and
rganization of living systems—something we have known for
ore than a hundred years. It is common to all organisms that
evelop from a single fertilized egg. Unfortunately, along with
he rapid progress of molecular biology, many scientists have
a
c
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ome to consider molecular bioactive effects as the functions of
olecules and not cells. However, we would like to emphasize
hat all molecules exerts their biological function through target
ells. The Nobel Prize-winning Sydney Brenner proposed that
he correct level of abstraction is the cell and provided an out-
ine of CELLMAP, a design for a system to organize biological
nformation [364]. This holistic approach is based on the idea
hat complex wholes cannot be understood by a study of their iso-
ated parts. When many components are put together, especially
ith interactions that are nonlinear, new emergent properties
an only be comprehended in the context of the whole sys-
em. In essence, molecules tell us nothing about cells and their
ehavior, and neurons tell us nothing about brains and how they
ork. The key is that we have a map of the molecules within
he cells and a map of the cells in the whole body. Even for
icrobes, the cells also constitute a complex cell communica-
ion network through their interactions, and their cross-talk in
ignaling pathways and metabolic networks. When choosing the
evel of the cell we can adopt a uniform conceptual architecture
or all levels, viewing the organism as a network of interac-
ing cells in the same way as we view the cell as a network of
nteracting molecules. Transcription factors and, in particular,
ssemblages of these, are special devices that not only interact
ith each other, but also with special DNA sequences in gene
romoters.
Based on the approach outlined above, we determined that
lmost all foods include macronutrients, vitamins, phytochemi-
als, and even toxins that affect immunomodulation, activation
r suppression of signal transduction, and metabolic regula-
ion. Moreover, different experiments performed with the same
amples result in remarkable different, and even contradictory,
ndings. So what can these data can tell us? Which agents are
eneficial for our health? In order to resolve these problems,
e have to be clear as to which component is the agent of the
iological function and how it functions in  vivo.  We strongly
uggest that the cell alone exerts, only cell is the executor of
iological functions, and cell exerts its functions through inter-
ctions each other cells, and that these interactions constitutes
 cellular communications network that occurs via  by signaling
olecules in circulations.
.  Do  we  really  have  a  mobile  cell  communication
etwork  in  our  body?
The immune system is formed by a complex network of dif-
erent cell types including lymphocytes, DCs, macrophages, and
eutrophils. Each has a specific function, but all share the ability
o move continuously throughout the body, constantly surveying
eripheral tissues and lymphoid organs for the presence of poten-
ial pathogens. These cells are able to change their homeostatic
ecirculation program when they are informed of an infected
ite. Recruitment of immune cells to the site of infection is crit-
cal for mounting an immune response to fight off and clear
way the invaders. Obviously, this is an information communi-
ation process, especially for mobile cells, such as leukocytes,
nd certainly confirms mobile cell communication network.
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.1.  The  evidence  for  the  objective  existence  of  a  mobile
ell communication  network
The chemokine/chemokine receptor family orchestrates
iverse patterns of immune cell migration. Chemokines are
mall cytokines characterized by their ability to induce direc-
ional migration of cells by binding to chemokine receptors.
urrently, more than 50 chemokines and 20 chemokine recep-
ors have been described. All chemokines bind to receptors that
elong to the seven-transmembrane GPCR family. The signaling
athways initiated by ligand binding to the GPCRs lead to acti-
ation of kinases responsible for signal transduction, changes in
ntracellular calcium levels, and phosphorylation and activation
f transcription factors. This results in molecular and functional
hanges in effector cells that allow them to migrate toward a gra-
ient of chemokines. Genes encoding proteins involved in cell
dhesion (integrins, laminins, and cadherins) are of particular
ignificance to chemokine-induced alterations in gene expres-
ion as they mediate the attachment of immune/tumor cells to
arious target tissues [365].
The classical leukocyte adhesion cascade involves the follow-
ng key steps: (i) leukocyte capture and rolling, (ii) activation and
rrest, and (iii) transendothelial migration. To mediate an effec-
ive response, leukocytes must find their way to sites of infection
r inflammation. Leukocyte invasion of tissues can be induced
y several substances—including IL-1, TNF-, and LPS—that
ause leukocyte emigration when injected in  vivo. All such com-
ounds induce the production of chemoattractants, which in
urn cause leukocyte migration. Therefore, chemotactic activ-
ty includes receptor-mediated gradient perception and must be
easured by the ability of a chemoattractant to induce directed
eukocyte migration. The magnitude of the cellular response
licited by chemokines is dictated by the level of receptor expres-
ion at the plasma membrane, which is a balance of finely tuned
ndocytic and recycling pathways. Recent data have revealed
hat receptor trafficking properties can drive chemokine recep-
ors to lysosomal degradation or recycling pathways, producing
pposite effects on the strength of the intracellular signaling
ascade [366].
The route for leukocyte emigration to a specific target site is
uided and regulated by adhesive cascades, which are mediated
y three sequential and partially overlapping steps: initiation
y selectin-mediated, capturing and rolling, and chemokine-
riggered activation and integrin-dependent arrest on endothelial
mmunoglobulin superfamily (IgSF) ligands. Different selectin
nd integrin family members, together with diverse endothelial-
isplayed chemokines, provide large combinatorial specificity
o this process.
Chemokine signals activate leukocyte integrins and actin
emodeling machineries critical for leukocyte adhesion and
otility across vascular barriers. The arrest of leukocytes at
arget blood vessel sites depends on rapid conformational
ctivation of their 4 and 2 integrins by the binding of
ndothelial-displayed chemokines to leukocyte GPCRs. A uni-
ersal regulator of this event is the integrin-actin adaptor talin-1.
hemokine-stimulated GPCRs can transmit within fractions of
econd signals via  multiple Rho GTPases, which locally raise

T
i
cman Wellness 1 (2012) 26–60
lasma membrane levels of the talin activating phosphatidyl
nositolPtdInsP2 (PIP2). Additional pools of GPCR-stimulated
ac-1 and Rap-1 GTPases together with GPCR-stimulated PLC
nd PI3K family members regulate the turnover of focal con-
acts of leukocyte integrins, induce the collapse of leukocyte
icrovilli, and promote polarized leukocyte crawling in search
f exit cues. Concomitantly, other leukocyte GTPases triggers
nvasive protrusions into and between endothelial cells in search
f basolateral chemokine exit cues [367].
Leukocyte trafficking from the bloodstream to inflamed
arget tissues across the endothelial barrier is an essential
esponse. Leukocyte adhesion, locomotion, and diapedesis
nduce signaling in endothelial cells, and this is accompanied by
 profound reorganization of the endothelial cell surfaces which
re only beginning to be unveiled. The coordination between
hese different endothelial membrane-remodeling events proba-
ly provides the road map for transmigrating leukocytes to find
xit points in the vessel wall [368].
To fulfill their duties, leukocytes must be able to counteract
he pushing force generated by the flow, arresting on the surface
f endothelial cells and transmigrating into tissues. Everything
ust be done within a few seconds or less to cope with the timing
mposed by flow dynamics [369]. Leukocyte rolling on endothe-
ial cells and other P-selectin substrates is mediated by P-selectin
inding to P-selectin glycoprotein ligand-1 expressed on the tips
f leukocyte microvilli. Leukocyte rolling is a result of rapid, yet
alanced formation and dissociation of selectin–ligand bonds in
he presence of hydrodynamic shear forces [370]. Rolling ini-
iates with the first step of capture, this can result in rolling
long the vessel endothelium followed by slow rolling, activa-
ion, and firm arrest. The free flowing marginated neutrophils
ether and roll along the vessel endothelium through reversible
nd rapid interactions between the selectin family of adhesion
olecules expressed on endothelial cells (P, E-selectin) or neu-
rophils (L-selectin) with their carbohydrate ligands expressed
n the opposing cell to mediate the primary steps of capturing
nd rolling [371].
.2.  The  GI  tract  is  the  regulatory  center  of  the  mobile  cell
ommunication network
Studies exploring the relationships between leucocytes and
hemokines/chemokine receptors in the GI are currently under-
ay. Considering the large area of the GI tract (a surface area of
lmost 400 m2 in man), it is not surprising that it has developed
oth immunologic and non-immunologic means of protection.
urthermore, almost all receptors are expressed throughout the
I tract. As mentioned above, various signals can be secreted
nd released into bloodstream, including cytokines, chemokines,
nd hormones, after the ingestion of oral medicines, drugs, and
unctional foods.
When the GI tract is faced with an antigen, it can be induced
o express pro-inflammatory cytokines such as IL-1  and TNF-
, which cause leukocyte emigration and cell communication.
herefore, the GI tract should be considered the center of the
mmunodefence system as well as the center of mobile cell
ommunication.
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.3.  How  can  we  build  a  cell  communication  network?
Frankenstein et al. [372] analyzed the cytokine network with
he aim of uncovering its characteristic features: connection
ensity, motifs and anti-motifs, distinct cell roles, and network
uper-family associations. In their model, cytokine connections
etween and among immune and body cells were obtained man-
ally from an internet database, the Cytokines  Online  Pathfinder
ncyclopedia. They automatically transformed the raw data into
 network format designating cells as nodes and cytokine con-
ections as edges, and used an information-based methodology
o uncover the large-scale architecture of the cytokine networks
hat connect immune and non-immune cells. The density of each
f 113 different published networks was also computed, and
nterestingly, the immune cytokine sub-network was found to
e the densest of networks with a density score of 0.61; it was
ollowed by the non-immune (body cell) sub-network which
ad a density score of 0.4, and the neuronal network of the mon-
ey brain, which had a score of 0.15. These findings indicate
hat the density of the mobile cell communication network is
onsiderably greater than that of the nerve-mediated wired cell
ommunication network. However, this is only based on data
nd an ideal system and so cannot be considered representative
f the physical facts.
We discovered a method for developing a cell communi-
ation network that can be applied with human volunteers
nd oral administration of medicines, drugs, and functional
oods. The hypothesis of a mobile cell wireless communica-
ion network was suggested based on immunological data and
he complex interactions between dietary constituents and GI
ucous receptors as well as the molecular biology of cell
ignaling and its effects [373]. The key points of this hypoth-
sis include: (1) the so-called “cytokine networks” are the
atural signal transduction system of cell communications; (2)
obile cells, especially leukocytes, communicate with each
ther across the area network through paracrine or autocrine
ignaling, and across the whole communication network (which
ncludes not only mobile cells but also immobilized cells and
ocal and remote communication) by telecrine or endocrine
ignaling or neurosecretion; (3) three networks of intercellular
ommunication can be associated with cytokine and chemokine
ecretion; one is limited to the cells of the immune system
immune cells), one to parenchymal cells of organs and tissues
body cells), and one involves interactions between immune
nd body cells; (4) these different cell communications inter-
ct to form a complex network, including wired and wireless
onnections; (5) bioactive molecules-cytokines/cytokine recep-
ors and chemokines/chemokine receptors play key roles in
ell communications; (6) the blood concentration of these sig-
als (cytokines and chemokines) is very low (pg), but they
an cascade via  different signaling pathways in target cells;
7) the cytokine and chemokine signals are transported via
he bloodstream to any part of the body, and they exert
ifferent functions in different cells. However, when they
re transported via  the blood, they do not interfere with
ach other; (8) mobile cells roll through the vessel epider-
is and are guided by adhesion proteins; (9) because these
o
m
cman Wellness 1 (2012) 26–60 51
ytokines or chemokines are transported by the circulatory sys-
em, a 2–3 mL blood sample from a volunteer will be data
ich.
We [374] investigated the physiological functions of Pho-
iota nameko  polysaccharides (PNPS-1), and mapped out
he cell communication network diagram. This showed that
NPS-1 possessed significant anti-inflammatory activity in
umans in  vivo.
0.  Conclusions  and  future  perspectives
0.1. Conclusions
The above data indicate that at least some functional foods
xert their effects by interacting with numerous complex recep-
ors located throughout the GI tract. The gut is not only a nutrient
ecognition and control system, but also a signal transducer,
euroendocrine sensor, and immunological recognition and pre-
entation system. These complex information exchange systems
onstitute a symphonic signal transduction network between the
ifferent cells of the GI tract and immobilized cells in organs as
ell as mobile cells in the blood. Functional foods may exert
heir effects via  some of these networks in  vivo.
Nutrients are taken up by complex transport systems that are
ompactly and stoichiometrically coupled with ion channels,
a+–K+pumps, sensors, and signaling pathways. Nutrients and
heir homeostasis must therefore be coordinated with integral
hysiological, metabolic, immunological, and neuroendocrine
ystems.
In the gut, there is a delicate balance between the need to rec-
gnize pathogens and dietary ingredients to prevent unwanted
mmune responses to food antigens or the normal intestinal
ora, and the need to simultaneously allow for adequate nutri-
nt uptake. As the GI tract covers a large surface area, it has
eveloped both immunologic and non-immunologic means of
rotection.
Intestinal cells can express adhesion molecules constitutively,
nd can be upregulated by cytokines, chemokines, and other
ro-inflammatory molecules, including dietary ingredients and
icrobial metabolites. In addition to mediating adhesion, some
f these molecules are also costimulatory during intercellular
ignaling. To date, almost all membrane receptors have been
bserved on the mucosa, which indicates that these receptors
an interact with their specific ligands in the GI tract and thereby
ense the environmental conditions, especially the nutritional
tatus of the body, via  the circulatory system.
Probiotics are the most well characterized dietary bioactive
ompounds. The beneficial effects of probiotics mainly rely on
heir influence on the composition of the gut microbiota and their
bility to generate fermentation products with diverse bioactive
oles. The gut microbiota may constitute a complex metabolic
etwork for communication relating to dietary nutrition and the
ost. The challenge may be to determine the temporal dynamics
f metabolic communication between the host, diet, and gut
icrobiota, and to evaluate their real effects in  vivo.
Some functional foods cannot be absorbed, but do impact
ytokines and chemokines. Non-digestible oligosaccharides
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ay be supplemented to modulation immune responses in the
ntestine. IECs lining the mucosa are known to express car-
ohydrate (glycan)-binding receptors that may be involved in
odulation of the mucosal immune response. The GI immune
ystem is the largest and most complex immunological tissue
n the human body and it can discriminate between potentially
angerous antigens and beneficial probiotics and microbes. IECs
xpress several receptors that recognize antigens present in the
ntestinal lumen. These receptors could be the most impor-
ant information delivering systems and have critical bioactive
ffects in association with functional foods or oral medicines.
A series of communications occur between the gut/brain,
ut/endocrine system, gut/liver, gut/lungs, gut/cardiovascular
ystem, and even the gut/reproductive system. The evidence
trongly suggests that the gut functions as an information cen-
er in this cyclic system. The cell is the fundamental unit of
tructure, function, and organization of living systems. So the
ell, and only the cell, is the agent of biological function, and
t exerts its effects through interactions with other cells, which
onstitutes a cell communication network operated by signaling
olecules in the circulatory system.
The density of the immune cytokine sub-network is the dens-
st of networks, which suggests that the density of the mobile
ell communication network is considerably greater than that of
he nerve-mediated wired cell communication network. How-
ver, this finding was based on an ideal system, and so is far
rom the physical truth. We discovered a method for devel-
ping a cell communication network that can be conveniently
pplied in human volunteers to experiment with oral admin-
stration of different medicines, drugs, and functional foods.
ecause cytokines and chemokines are transported by circu-
ation, a 2–3 ml blood sample from volunteer can be data rich.
0.2. Future  perspectives
Although food intake is required to ensure adequate nutri-
ion, it also has to be stringently regulated according to the
hysiology of the metabolic systems and homeostasis of each
ndividual. Once excessive nutrients are ingested, or too little, or
f nutritional intake is not balanced, then illness occurs. This pro-
ess is intensively regulated by the GI tract. Furthermore, the GI
ract also acts as an information exchange system through which
rganisms distinguish, recognize, identify, and sense the com-
lex microecological environment of the lumen as well as its
olecular structure and that of the world around us. This means
hat almost everything will affect our health via  the GI informa-
ion exchange system, including nutrients, microbes, functional
oods, medicines, pathogens, vaccines, and even toxins. Based
n these ideas, we believe that future research will focus on the
ollowing: (1) the biological roles of functional food compo-
ents are being investigated since their metabolites and effects
ay depend on the gut microbiota, which may differ between
ndividuals; (2) advances in our understanding of the interac-
ions that occur between bioactive food compounds and specific
ntestinal bacteria can contribute to better elucidation of both
ositive and negative interactions in  vivo; (3) increased under-
tanding of the intestinal targets of nutritional regulation mayman Wellness 1 (2012) 26–60
xtend beyond incretin release to mechanisms entirely confined
o ECs. Characterization of these EC-based mechanisms regu-
ating nutrient absorption and metabolite trafficking will help
s to distinguish the passive effects of nutrient transport on
nergetic status from active signaling events; (4) based on the
igh throughput microarray and molecular interaction approach,
creening for more sensors or receptors throughout the GI will
e possible. Existing functional food data will need to be com-
lemented by experiments in  vivo  in which the expression of
he potential nutrient sensor or receptor can be manipulated
ith temporal resolution and specifically in the intestine; (5)
everal tasks should be addressed in the near future in order to
nsure the safe and successful development and delivery of func-
ional foods. These include the identification of the suitable oral
elivery systems, improved understanding of conditions affect-
ng their biological activity, and of the development of a gold
tandard method for the functional evaluation of functional foods
r medicines in humans in  vivo. The cell communication net-
ork described above appears to be the best candidate method
urrently available.
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